Advertisements


Zosano Pharma: Q1 Earnings Insights

Zosano Pharma (NASDAQ:ZSAN) reported its Q1 earnings results on Friday, May 13, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Zosano Pharma reported in-line EPS of $-1.75 versus ...Full story available on Benzinga.com.....»»

Category: earningsSource: benzingaMay 13th, 2022

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes. Myriad Genetics, Inc. MYGN has been gaining from spectacular improvement in Pharmacogenomics testing revenues, along with growth in tumor profiling and GeneSight test volumes. Recent product launches looks encouraging. However, stiff competition and foreign exchange headwinds do not bode well for the stock.Over the past year, the Zacks Rank #3 (Hold) stock has lost 16.1% compared with the 37.9% decline of the industry and 9% rise of the S&P 500.The renowned molecular diagnostic company has a market capitalization of $2.15 billion. The company’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, delivering an average surprise of 2.9%.Let’s delve deeper.Factors At PlayHuge Potential in Oncology Testing: The company is boding well to cash on the huge potential in the breast cancer screening market. During the fourth quarter of 2021, Myriad Genetics’ Oncology business grew 12% year over year. The company noted that in early 2022, it will launch Precise Tumor for molecular tumor profiling – a part of a suite of Precise Oncology Solutions that combines the company’s MyRisk germline hereditary cancer testing technology and its MyChoice CDx companion diagnostic test with a Myriad tumor profiling test powered by Illumina’s TSO500 technology.myChoice CDx Progresses Well: Myriad Genetics' progress across the globe, with respect to myChoice CDx test, seems impressive. The company recorded strong revenue growth in the reported quarter from companion diagnostics, including significant revenue share from its proprietary myChoice CDx test. During the fourth-quarter earnings update, the company announced plans to expand its market-leading FDA-approved companion diagnostic test, MyChoice CDx, to other indications like breast, prostate and pancreatic cancers, for expanded pharma clinical trials and commercial testing.Product Launches Looks Encouraging: Myriad Genetics launched a slew of products in recent months. The company, in February 2021, launched the new Vectra Cardiovascular Risk assessment that can predict the risk for cardiovascular events in patients with rheumatoid arthritis.Image Source: Zacks Investment ResearchIn August 2021, the company launched its myRisk hereditary cancer test with riskScore for all ancestries, which is the only polygenic breast cancer risk assessment available. With riskScore, clinicians can gain critical insights to help treat women with increased risk of breast cancer who likely do not have an identifiable mutation in one of the breast cancer genes. Per the fourth-quarter earnings update, the company plans to launch a combined prenatal and carrier screening test, FirstGene, in 2023.DownsidesIncreasing Competition: With the entry of new players, imminent price competition is another cause of concern. Per management, Myriad Genetics is currently facing competition in its key BRACAnalysis market. The company expects competition to intensify in its current fields with recent advancements in technology.Foreign Exchange Headwinds: Myriad Genetics receives a considerable portion of its revenues and pays a portion of its expenses in foreign currencies. As a result, the company remains at risk of exchange rate fluctuations between foreign currencies and the U.S. dollar.Estimate TrendOver the past 60 days, the Zacks Consensus Estimate for Insulet’s EPS has moved down by 52.2% to 11 cents.The Zacks Consensus Estimate for 2022 revenues is pegged at $683.2 million, suggesting a 1.1% fall from the year-ago reported number.Key PicksFew better-ranked stocks in the broader medical space are McKesson Corporation MCK, AMN Healthcare Services, Inc. AMN and Bio-Rad Laboratories, Inc. BIO.McKesson, carrying a Zacks Rank #2 (Buy), reported third-quarter fiscal 2022 adjusted EPS of $6.15, which beat the Zacks Consensus Estimate of $5.38 by 14.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.McKesson has a long-term earnings growth rate of 11.8%. MCK has gained 55% compared with the industry’s 5.7% growth in the past year.AMN Healthcare, carrying a Zacks Rank #1, has a long-term earnings growth rate of 16.2%. The company's earnings surpassed estimates in the trailing four quarters, delivering a surprise of 19.5%, on average.AMN Healthcare has outperformed its industry over the past year. AMN has gained 34.5% versus the 60.4% industry decline.Bio-Rad reported fourth-quarter 2021 adjusted EPS of $3.21, which surpassed the Zacks Consensus Estimate by 11.9%. It currently has a Zacks Rank #2.Bio-Rad has an earnings yield of 2.3%, which compares favorably against the industry’s negative yield. BIO's earnings surpassed estimates in the trailing four quarters, the average surprise being 66.9%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report BioRad Laboratories, Inc. (BIO): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMar 17th, 2022

Veeva Systems (VEEV) Digital Tools Boost Patient Engagement

Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams. Veeva Systems Inc. VEEV recently unveiled two new digital tools at the European Veeva Commercial and Medical Summit Connect event. The company unveiled enhancements in digital tools that add new ways for seamless communication among healthcare professionals (HCPs) and field teams.The company showcased Veeva CRM Engage Connect compliant messaging and content sharing capabilities along with the newest enhancements to Veeva CRM.The recent development is likely to enhance Veeva Systems cloud-based software solutions.More on Engage ConnectEngage Connect is part of the Veeva Engage platform that allows anytime, any channel engagement through video, phone calls, contactless in-person interactions or chat. The HCPs will be able to connect and meet with participating life science commercial teams using their existing Veeva Engage app, available in the Apple app store and Google Play.Veeva Engage Connect enables easy chat-like messaging and content sharing, as pharma representatives and medical science liaisons (MSLs) can securely chat with HCP customers anytime, anywhere to provide timely information on potential treatments.Image Source: Zacks Investment ResearchEngage Connect will be available from the next month as part of the Veeva Engage app, which is currently used by over a million HCPs for digital meetings.More on Veeva CRMVeeva CRM offers a purpose-built library of applications customized for specific roles. It has been fully optimized to enhance productivity with the right experience on the right device.Veeva CRM is used by 42 of the top 50 pharmaceutical companies and growing biopharma innovators to provide the best customer engagement solutions.  Medical teams can now find, assemble, present and share scientific content as easily from their home office as in the field.Significance of the New Digital ToolsWith Veeva Engage Connect, the field teams can quickly connect with HCPs in a more personal and easy way through compliant texts and scheduling meetings. The teams can also share patient resources. Veeva Engage Connect is helping cement relationships between HCPs and life sciences companies by offering convenient two-way engagement across several companies and brands in a single app.Veeva CRM offers the tracking, visibility and insights life sciences companies with the need to customize virtual and in-person interactions with HCPs across channels.Industry ProspectsPer a report by Grand View Research, the global customer relationship management market size was valued at $43.7 billion in 2020 and is expected to register a CAGR of 10.6%.Rising demand for automated engagement with customers, focus on improving the scope of digital operations and bettering customer experience and services are driving the market.Recent DevelopmentsIn November 2021, Veeva Systems announced that Veeva Vault Quality Suite was adopted by the Center for Breakthrough Medicines (“CBM”) to advance the development and manufacturing services of sponsors. By adopting a unified quality solution, CBM can boost manufacturing efficiency and increase partnerships across departments, suppliers and customers.In October 2021, Veeva Systems announced that the number of emerging biotechs using Veeva Vault CDMS to run faster, more effective oncology trials rose to more than double in the last year. These companies are adopting Vault CDMS to benefit from an easy-to-use system that doesn’t require custom functions.Price PerformanceShares of the company have gained 12.1% in a year against the industry’s fall of 5.7%.Zacks Rank and Other Key PicksVeeva Systems currently carries a Zacks Rank #2 (Buy).A few other top-ranked stocks from the broader medical space are Chemed Corp. CHE, Laboratory Corporation of America Holdings or LabCorp LH and Medpace Holdings, Inc. MEDP.Chemed, carrying a Zacks Rank #2, has a long-term earnings growth rate of 7.7%. The company surpassed earnings estimates in three of the trailing four quarters and missed in one. It has a trailing four-quarter earnings surprise of 5.6%, on average.Chemed has outperformed the industry in the past year. CHE has gained 3.7% against a 35.6% decline of the industry.LabCorp, carrying a Zacks Rank #2, reported third-quarter 2021 adjusted earnings per share (EPS) of $6.82. The bottom line surpassed the Zacks Consensus Estimate by 42.9%. Revenues of $4.06 billion outpaced the Zacks Consensus Estimate by 13.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.LabCorp has an estimated long-term growth rate of 10.6%. LH has a trailing four-quarters earnings surprise of 25.7%, on average.Medpace reported third-quarter 2021 adjusted EPS of $1.29, surpassing the Zacks Consensus Estimate by 20.6%. Revenues of $295.57 million beat the Zacks Consensus Estimate by 1.2%.Medpace has an estimated long-term growth rate of 16.4%. MEDP has a trailing four-quarter earnings surprise of 11.9%, on average. It currently sports a Zacks Rank #1. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksNov 22nd, 2021

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

Highlights: Revenue of $167.3 million up 15% year-over-year. Excluding revenue from divested businesses, revenue increased 27% year-over-year Diluted GAAP earnings per share (EPS) of $0.30 and adjusted EPS of $(0.02) SALT LAKE CITY, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2021 and provided an update on recent business performance and strategic transformation plans.   "We are encouraged by our third quarter performance, and the execution of our teammates on our strategic growth and transformation plans that resulted in year-over-year growth in test volumes, margins and revenue," said Paul J. Diaz, President and Chief Executive Officer. "The quality and accuracy of our products and improving customer service levels continue to position our business for sustainable growth and profitability. I want to thank all of our 2,400 Myriad Genetics teammates for their commitment to advancing the health and well-being of all of our patients. We are encouraged by the growing market opportunities in our core businesses and see significant potential to expand access to quality genetic testing and precision medicines that improve health outcomes and access to needed healthcare services." Financial and Operational Highlights: Diagnostic test volumes of 252,000 increased 15% year-over-year. Sequential volume was impacted by constraints in access to healthcare providers due to the COVID-19 pandemic, the impact of the Delta variant strain, and typical summer seasonality. Hereditary cancer volumes for the quarter were flat year-over-year and decreased 7% sequentially. Prenatal test volumes in Women's Health increased 7% year-over-year and decreased 10% sequentially. Tumor profiling test volumes in Oncology increased 33% year-over-year and decreased 15% sequentially. Pharmacogenomics test volumes in Mental Health increased 71% year-over-year and 6% sequentially. Overall, average selling price (ASP) was stable year-over-year and sequentially after excluding positive revenue adjustments related to better-than-expected cash collections on tests ordered in prior periods. Total revenue in the quarter was $167.3 million, an increase of 15% year-over-year. Excluding the divested business revenue, RBM, Autoimmune and myPath, quarterly revenue increased 27% year-over-year. The following table summarizes year-over-year revenue changes by product category:   Three months ended (in millions) September 30, 2021   September 30, 2020   % Change Product revenues:               Hereditary Cancer $ 79.4   $ 80.5   (1 ) % Prenatal   23.6     16.6   42    % Tumor Profiling   32.9  *   17.0   94    % Pharmacogenomics   24.1     11.9   103    % *Tumor Profiling revenue for the three months ended September 30, 2021 was positively impacted by a milestone payment of $4.0M   GAAP gross margin in the quarter was 71.4%; adjusted gross margin was 71.7%, which improved 190 basis points year-over-year. GAAP total operating expenses in the quarter were $199.4 million; adjusted total operating expenses decreased $1.6 million sequentially to $121.5 million. GAAP operating loss in the quarter was $(79.9) million, declining $40.3 million year-over-year; adjusted operating loss was $(1.4) million, improving $10.7 million year-over year. Diluted GAAP EPS in the quarter were $0.30, improving $0.50 year-over-year; adjusted EPS were $(0.02), improving $0.13 year-over-year. Closed the sale of Myriad Autoimmune's Vectra testing business on September 13, 2021. Ended the quarter with $413.6 million in cash, cash equivalents and investments. "While we still have a lot of hard work ahead of us, we are now better positioned for growth across all of our business segments as we look to 2022 and beyond," said Diaz. "Our balance sheet is strong. As a result, we can now focus on investing further in the opportunities we see in the emerging technologies, R&D and commercial strategies that elevate our products to their full potential including, acquisitions, new partnerships, and new business development efforts. We look forward to expanding access to vital genetic testing, and precision medicine, making it easier for patients and partners to engage with us, and delivering sustainable and profitable results for all of our shareholders." Business Performance and Highlights: Women's HealthIn the Myriad Women's Health business, Myriad serves women assessing their risk of cancer, and those who are pregnant or planning a family. Women's Health delivered revenue of $59.1 million in the quarter, an increase of 6% year-over-year and a decrease of 12% sequentially. Hereditary Cancer With the launch of the first polygenic breast cancer risk assessment score validated for women of all ancestries, Myriad further strengthened its industry-leading MyRisk® Hereditary Cancer test and significantly expanded access to genetic testing. Now enhanced with RiskScore® for all ancestries, MyRisk provides 5-year and lifetime breast cancer risk assessment for all women not previously diagnosed with breast cancer. RiskScore results are informed by a combination of genetic markers, clinical and biological variables, personal and family history, and ancestry-specific data. RiskScore is available at no additional cost to women who take the MyRisk test. Prenatal The company continues to see increasing momentum from its Prequel™ noninvasive prenatal screening (NIPS) test including proprietary AMPLIFY™ technology, which dramatically enhances the test's performance and works to reduce test failure rates so that patients may avoid unnecessary invasive procedures. In late 2022, the company plans to launch a novel prenatal test that will deliver the clinical value of both Prequel and Foresight to more expectant parents. The novel offering will simplify the NIPS and carrier screening workflows, which currently involve several samples and different tests, and deliver key clinical content of Prequel and the Foresight carrier screen test from a single maternal sample. The combined offering will provide a single prenatal test that is simple, accurate and will allow more patients to get answers faster. OncologyMyriad's Oncology business provides hereditary cancer testing, including MyRisk®, for patients who have cancer. It also provides tumor profiling products such as the EndoPredict® breast cancer prognostic test, the Prolaris® prostate cancer test, and the myChoiceCDx® companion diagnostic test for predicting response to PARP inhibitors. The Oncology business delivered revenue of $76.8 million in the quarter, an increase of 32% year-over-year and a decrease of 2% sequentially. The company made progress towards launching its combined offering of somatic, germline and CDx for ovarian cancer patients. The new offering, planned for launch in early 2022, combines Myriad's leading germline hereditary cancer test (MyRisk), Myriad's FDA approved companion diagnostic test (myChoiceCDx), together with a Myriad branded tumor profiling test powered by Illumina's TSO500 and run by Intermountain's Precision Genomics. With Myriad's new combined offering, patients and their healthcare providers will receive one comprehensive solution from one laboratory with one team of scientists interpreting the results thereby significantly improving the quality and ease of use of the results. The combined product offering will be sold through the Myriad Oncology sales force throughout the entire U.S. Mental HealthMyriad's Mental Health business consists of the GeneSight® psychotropic test that covers 61 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. In the pharmacogenomic category, GeneSight delivered revenue of $24.1 million in the quarter, an increase of 103% year-over-year and 7% sequentially. GeneSight saw a strong increase in new ordering providers with nearly 2,700 physicians ordering GeneSight for the first time in the quarter. The total number of ordering physicians increased 6% sequentially. The Mental Health business has successfully implemented its ongoing commercial transformation with the rightsizing of its field sales force, growing its inside sales force, and executing a robust digital marketing plan to meet patients and clinicians where they are searching for mental health treatments online. Business DivestituresOn July 1, 2021, the company completed the sale of its wholly-owned subsidiary, Myriad RBM, Inc. to Q2 Solutions. Gross proceeds of $197.0 million in cash. Recognized gain on sale of assets of $121.0 million. On September 13, 2021, the company completed the sale of select operating assets and intellectual property, including the Vectra® test, to Laboratory Corporation of America Holdings.   Gross proceeds of $150.0 million in cash. Recognized loss on sale of assets of $0.6 million. Recognized loss on inventory of $11.7 million. The company recorded $48.0 million for the potential qui tam settlement against Crescendo Bioscience, Inc. The company intends to use a portion of the total divestiture gross proceeds of approximately $380.0 million to fund investments in technology and commercial efforts and fund the potential qui tam settlement relating to Crescendo Bioscience, Inc. The proceeds were also used to paid down its revolving credit facility. Financial GuidanceGiven the continued unpredictability surrounding the COVID-19 pandemic (and its variant strains) as well as the impact it continues to have on the healthcare environment, customer behavior and the ability to market tests to physicians, the company will not provide financial guidance for the fourth quarter ending December 31, 2021 or fiscal year 2021. We expect to resume providing financial guidance in early 2022. Conference Call and WebcastA conference call will be held today, Tuesday, November 2, 2021, at 4:30 p.m. EDT to discuss Myriad's financial results and business developments for the third quarter 2021. The dial-in number for domestic callers is 1-800-920-2776. International callers may dial 1-212-271-4651. All callers will be asked to reference reservation number 21998401. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call and slide presentation will be available through a live webcast at www.myriad.com. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, RiskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. Revenue by Product (Unaudited):   Three months ended September 30, (in millions) 2021   2020       WH Onc MH Other Total   WH Onc MH Other Total   % Change Hereditary Cancer $ 35.5   $ 43.9   $ —   $ —   $ 79.4     $ 39.2   $ 41.3   $ —   $ —   $ 80.5     (1 ) % Tumor Profiling —   32.9   —   —   32.9     —   17.0   —   —   17.0     94   % Prenatal 23.6   —   —   —   23.6     16.6   —   —   —   16.6     42   % Pharmacogenomics —   —   24.1   —   24.1     —   —   11.9   —   11.9     103   % Autoimmune —   —   —   7.3   7.3     —   —   —   9.1   9.1     (20 ) % Other —   —   —   —   —     —   —   —   0.6   0.6     (100 ) % Total molecular diagnostic 59.1   76.8   24.1   7.3   167.3     55.8   58.3   11.9   9.7   135.7     23   % Total pharma and clinical —   —   —   —   —     —   —   —   9.5   9.5     (100 ) % Total Revenue $ 59.1   $ 76.8   $ 24.1   $ 7.3   $ 167.3     $ 55.8   $ 58.3   $ 11.9   $ 19.2   $ 145.2     15   %   Nine months ended September 30, (in millions) 2021   2020       WH Onc MH Other Total   WH Onc MH Other Total   % Change Hereditary Cancer $ 105.3   $ 136.2   $ —   $ —   $ 241.5     $ 97.3   $ 107.7   $ —   $ 0.6   $ 205.6     17   % Tumor Profiling —   94.4   —   —   94.4     —   41.2   —   —   41.2     129   % Prenatal 76.7   —   —   —   76.7     53.5   —   —   —   53.5     43   % Pharmacogenomics —   —   64.3   —   64.3     —   —   40.8   —   40.8     58   % Autoimmune —   —   —   28.2   28.2     —   —   —   26.8   26.8     5   % Other —   —   —   0.5   0.5     0.1   —   —   1.5   1.6     (69 ) % Total molecular diagnostic 182.0   230.6   64.3   28.7   505.6     150.9   148.9   40.8   28.9   369.5     37   % Total pharma and clinical —   —   —   24.2   24.2     —   —   —   32.9   32.9     (26 ) % Total Revenue $ 182.0   $ 230.6   $ 64.3   $ 52.9   $ 529.8     $ 150.9   $ 148.9  .....»»

Category: earningsSource: benzingaNov 2nd, 2021

2 Stocks of Relative Strength In Slowing Semiconductor Industry

While secular growth prospects for the Semiconductor - General industry remain, analysts are expecting a softening in demand, which is not reflected in the prices. STM and TXN look relatively safer bets at this point. Companies in the Semiconductor – General industry are at the forefront of the ongoing technological revolution based on HPC, AI, automated driving, IoT and so forth. These semiconductors also enable the cloud to function and help analyze the data into actionable insights that can be used by companies to operate more efficiently.  The pandemic led companies to ramp up technology investments in order to stay operational when it was unsafe for us to go to work or meet people. But since this meant that a lot of infrastructure was built out in advance, analysts currently expect demand to slow down in the near future. Longer-term trends continue to favor digitization, cloud, AI, etc., which will drive strong demand for semiconductors. This is not a great place to invest in right now, but STMicroelectronics and Texas Instruments look relatively attractive.About The IndustryThe companies grouped under the Semiconductor – General category produce a broad range of semiconductor devices, both integrated and discrete, like microprocessors, graphics processors, embedded processors, chipsets, motherboards, wireless and wired connectivity products, DLPs and analog, serving multiple end markets. The industry includes companies like NVIDIA, Texas Instruments, Intel and STMicroelectronics.According to the latest data from the Semiconductor Industry Association (SIA), global semiconductor sales in the first quarter of 2022 grew 23.0% to $151.7 billion. 2021 sales were up 26.2% to the highest-ever annual total. All regions grew, with the Americas up 40.1%, Europe 25.7%, Japan 20.4%, China 17.3% and Asia Pacific/All Other 17.9%. The 2022 projection of 8.8% growth was not revised.MainThemesBeing on the building-block side of technology, the industry stands to benefit from the proliferation of the Internet and the growing digitization of our lives, irrespective of the direction we move in the future. And since the pandemic has accelerated this move toward digitization, we are seeing a profound impact on the semiconductor industry. Demand for smartphones (a primary application of semiconductors) declined for the third straight quarter according to IDC and the outlook isn’t great because of inflation and supply chain concerns. The China lockdowns and Ukraine war are other negatives. So IDC expects smartphone shipments to grow 1.6% in 2022 (previous 3.0%), with the ASP continuing to expand until next year, when 5G handsets become cheaper. The other major chip consumer is the PC market, where the consumer and education segments are temporarily slowing down following two years of very strong growth. But commercial will continue growing strongly, according to IDC. But other segments are gaining in importance. AI for instance should grow strongly (MarketsandMarkets expects a 39.7% CAGR between 2021 and 2026, from $58.3 billion to $309.6 billion). In IoT, which is still evolving, Mordor Intelligence expects a 10.53% CAGR between 2021 and 2026 from $761.4 billion to $1,386.1 billion. Automotive electronics is another area of evolving needs and strong growth potential (Grand View Research estimates a 7.9% CAGR in 2021-2028, driven mainly by various safety systems. Moreover, cost of electronic components in automobiles are expected to jump from 35% of total vehicle cost to 50% by 2030. Automation and robotics, with increasing adoption across industrial operations, are other areas of growth. The strong end markets will drive continued demand for semiconductor components for years to come.Because of the growth potential in emerging markets, regulatory (and/or political) issues in China and the U.S., can play an increasingly important role. The government’s strong stance against prime trading partner China has cast a shadow over the space. Semiconductor companies in particular stand to benefit from a truce between the U.S. and China as the Chinese government’s drive to build its own industry requires collaborations with leading semiconductor players. Moreover, commercial sales to China would help fund costly R&D in the U.S. The government is more concerned about IP protection and is trying to delay as far as possible, China’s own technological maturity. Be that as it may, the $52 billion infusion from the CHIPS Act (when adopted) will be a big boost to the domestic semiconductor market.Because end devices have to be priced lower to reach more people, the pressure on companies to bring down cost remains. But although companies still find it advantageous to move operations to places where labor may be cheaper or where the proximity to manufacturing facilities can lower transportation and other cost, governments across the world are waking up to the strategic value of producing chips onshore. Tensions with China have also made regulators eager to develop alternative supply chains. Industry consolidation should continue however, as larger players add expertise and capacity through acquisitions. There’s also likely to be close collaboration with device makers, facilitating quicker consumption and better inventory management.   Zacks Industry Rank Indicates Deteriorating ProspectsThe Zacks Semiconductor-General Industry is a stock group within the broader Zacks Computer and Technology Sector. It carries a Zacks Industry Rank #197, which places it in the bottom 22% of more than 250 Zacks industries.The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates that near-term prospects aren’t too bright. Our research shows that the bottom 50% of the Zacks-ranked industries underperforms the top 50% by a factor of 1:2.An industry’s positioning in the top 50% of Zacks-ranked industries is normally because the earnings outlook for the constituent companies in aggregate is encouraging. The opposite is true for stocks in the bottom 50% of industries. In this case, the aggregate earnings estimate for 2022 while displaying an improving trend in the last few months, is up a mere 2.3% from the year-ago level. The aggregate earnings estimate for 2023 is down 17.9% from last year.                                       Before we present a few stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture.Industry Leads on Stock Market PerformanceTracking the performance of the Zacks Semiconductor – General Industry over the past year shows that the industry has traded higher than both the broader Zacks Computer and Technology Sector and the S&P 500 index.The industry lost 1% over the past year compared to the 21.3% loss of the broader sector and the 6.2% loss of the S&P 500 index.One-Year Price PerformanceImage Source: Zacks Investment ResearchIndustry???s Current ValuationOn the basis of forward 12-month price-to-earnings (P/E) ratio, which is a commonly used multiple for valuing semiconductor companies, we see that the industry is currently trading at 22.3X, which is its lowest multiple over the past year. However, the S&P 500 trades at 17.4X while the sector trades at ’s 20.3X, so the industry appears overvalued in both these comparisons.Over the last five years, the industry has traded as high as 34.34X, as low as 12.86X and at the median of 18.94X.Forward 12 Month Price-to-Earnings (P/E) RatioImage Source: Zacks Investment Research2 Stocks Worth Considering STMicroelectronics N.V. (STM): The company designs, develops, manufactures and markets a broad range of semiconductor integrated circuits and discrete devices used in a wide variety of microelectronic applications, including telecommunications systems, computer systems, consumer products, automotive products and industrial automation and control systems.STMicroelectronics continues to see strong demand across all except the imaging product line and all markets except China (because of pandemic-induced shutdowns). Favorable mix and strong pricing remain positive for profitability. Given its exposure to the automotive market, the replenishment of inventories across the automotive supply chain and the ongoing electrification and digitalization are positives, despite the lower-than-expected number of cars produced.   Industrial, the other significant end market for STMicroelectronics is currently being driven by factory automation, power and energy applications, as well as building and home control. Industrial electrification and digitalization are the main trends accelerating the increase in semiconductor content.STM beat the Zacks Consensus Estimate for the fourth quarter by 11.3%. In the last 30 days, the current year EPS estimate of this Zacks Rank #3 (Hold) stock increased 13 cents (4.1%).The shares of the company are up just 0.2% over the past year, mainly because of the pressure they have been under since the beginning of this year and particularly, since March.Price & Consensus: STMImage Source: Zacks Investment ResearchTexas Instruments, Inc TXN: Texas Instruments is an original equipment manufacturer of analog, mixed signal and digital signal processing (DSP) integrated circuits.Texas Instruments has significant exposure to the industrial and automotive markets, where the semiconductor shortage is driving strong demand and pricing strength. But like STM, the company also sees some impact from China’s pandemic-related shutdowns. TI is known for operating a flexible manufacturing model (including its 300mm facilities) that includes both internal capabilities and external sources, thus making it a bit of a defensive play in downcycles. But the secular growth prospects in its served markets coupled with the current chip shortage is driving the company to increase capacity. Those extra costs notwithstanding, Texas Instruments continues to generate solid cash flows. It also returns cash to investors through regular share repurchases and dividends. This is one of the steadiest performing companies and continues to deliver, quarter upon quarter.In the last quarter, Texas Instruments generated earnings that topped the Zacks Consensus Estimate by 8.3% on revenues that beat by 4.1%. The Zacks Consensus Estimate for 2022 is up 18 cents (2.0%) in the last 30 days.Shares of this Zacks Rank #3 company are down 7.9% over the past year, mainly due to the broad market weakness.Price & Consensus: TXNImage Source: Zacks Investment Research Just Released: The Biggest Tech IPOs of 2022 For a limited time, Zacks is revealing the most anticipated tech IPOs expected to launch this year. Concerns about Federal interest rates and inflation caused many private companies to stay on the bench- leading to companies with better brand recognition and higher growth rates getting into the game. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity. See the complete list today.>>See Zacks Hottest IPOs NowWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Texas Instruments Incorporated (TXN): Free Stock Analysis Report STMicroelectronics N.V. (STM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 27th, 2022

Agilent (A) Q2 Earnings Surpass Estimates, Revenues Rise Y/Y

Agilent's (A) results for the fiscal second quarter reflect strong momentum in the pharma and chemical & energy market. Agilent Technologies A reported second-quarter fiscal 2022 earnings of $1.13 per share, beating the Zacks Consensus Estimate by 1.8%. The bottom line increased 16.5% year over year.Revenues of $1.61 billion lagged the Zacks Consensus Estimate by 0.3%. The top line was up 5% on a reported basis and 7% on a core basis from the year-ago quarter’s level.The top-line growth was driven by continued strong growth in the pharma market. Also, solid momentum in the chemical & energy market remained a positive.In terms of major markets, Analytical Laboratory and Dx & Clinical accounted for 85% and 15% of total revenues each, up 8% and 5% on a core basis, respectively, from the corresponding prior-year quarter’s readings.However, lockdowns in China due to the coronavirus pandemic and the conflict in Ukraine remained headwinds during the fiscal second quarter.Agilent Technologies, Inc. Price, Consensus and EPS Surprise Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. QuoteSegmental Top-Line DetailsAgilent has three reporting segments, namely Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $896 million or 56% of its total revenues, up 2% on a reported basis and 4% on a core basis from the respective prior-year quarter’s levels. This was driven by a positive environment across key end-markets served, especially the Pharma and Chemical & Energy market. However, shutdowns in China affected the instrument platforms. Nevertheless, growth in other platforms and cell analysis aided the results.ACG: Revenues from the segment were $353 million, accounting for 22% of total revenues. Also, the top line improved 7% year over year on a reported basis and 10% on a core basis, driven by strong demand for services on BioPharma and LC-MS platforms. Also, solid contract revenue growth across the portfolio remained a tailwind.DGG: Revenues increased 14% year over year on a reported basis and 15% on a core basis to $358 million, accounting for the remaining 22% of total revenues. Top-line growth was attributed to the strength in NASD and genomics businesses.Operating ResultsFor the fiscal second quarter, gross margin in the LSAG segment contracted 90 basis points (bps) on a year-over-year basis to 59%. DGG gross margin expanded 260 bps on a year-over-year basis to 56%. ACG gross margin expanded 180 bps to 47.1%.Research & development costs were $115 million, up 5.5% year over year. Selling, general & administrative expenses were $386 million, which decreased 8.1% year over year.Operating margin for the fiscal second quarter was 25.3%, which expanded 140 bps on a year-over-year basis.Segment-wise, operating margin for LSAG was down 20 bps year over year to 25.5%. The DGG segment’s operating margin expanded 360 bps on a year-over-year basis to 25.5%. ACG operating margin was 24.6%, which expanded 360 bps from the year-ago quarter’s level.Balance SheetAs of Apr 30, 2022, Agilent’s cash and cash equivalents were $1.19 billion, up from $1.11 billion on Jan 31, 2022.Accounts receivables were $1.24 billion at the end of fiscal second-quarter 2022, up from $1.21 billion at the end of first-quarter fiscal 2022.Further, long-term debt was $2.730 billion for the reported quarter, in line with the prior quarter’s figure.OutlookFor the fiscal third quarter, management expects revenues of $1.625-$1.650 billion, suggesting growth between 7.2% and 8.8% on a core basis from the year-ago actuals. The Zacks Consensus Estimate for revenues stands at $1.66 billion.Non-GAAP earnings per share are expected to be $1.20-1.22. The Zacks Consensus Estimate for earnings is pegged at $1.20 per share.For fiscal 2022, management anticipates revenues in the band of $6.67-$6.73 billion, implying growth of 5.6-6.5% on a reported basis and 8-9% on a core basis from the fiscal 2021 tally. The Zacks Consensus Estimate for full-year revenues is pegged at $6.71 billion.Further, management raised its guidance for non-GAAP earnings per share from $4.80-$4.90 to $4.86-$4.93. The Zacks Consensus Estimate for earnings is pegged at $4.86 per share.Zacks Rank & Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold). Investors interested in the broader technology sector can consider some better-ranked stocks like Avnet AVT, Monolithic Power Systems MPWR and MaxLinear MXL. While Avnet and Monolithic Power Systems sport a Zacks Rank #1 (Strong Buy), MaxLinear carries a Zacks Rank #2 (Buy) at present.You can see the complete list of today’s Zacks #1 Rank stocks here.Avnet has gained 4.5% in the past year. The long-term earnings growth rate for AVT is currently projected at 37.2%.Monolithic Power Systems has gained 28.4% in the past year. The long-term earnings growth rate for MPWR is currently projected at 25%.MaxLinear has rallied 7.5% in the past year. The long-term earnings growth rate for MXL is currently projected at 20%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Avnet, Inc. (AVT): Free Stock Analysis Report Agilent Technologies, Inc. (A): Free Stock Analysis Report Monolithic Power Systems, Inc. (MPWR): Free Stock Analysis Report MaxLinear, Inc (MXL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

Tenet Healthcare (THC) Unit Conifer Offers Services to Brookwood

Tenet Healthcare's (THC) unit Conifer inks an agreement with Brookwood Baptist Health to deliver enhanced revenue cycle services to four of the remaining hospitals of the latter across Central Alabama. Tenet Healthcare Corporation’s THC subsidiary Conifer Health Solutions recently introduced a multi-year, multi-facility service deal with Central Alabama’s well-established healthcare network Brookwood Baptist Health to extend comprehensive revenue cycle services to the remaining four hospitals out of five operated by Brookwood Baptist Health. The services include patient access, eligibility enrollment services and accounts receivable management.The recent deal can be termed as an extension of the collaboration between Conifer and Brookwood Baptist Health. Management of the latter has credited Conifer with being a solid partner in optimizing its revenue cycle functions through technology-backed services over the years, thereby enabling the healthcare network to intensify its focus on other mission-critical precedences.With the latest service agreement, the Tenet Healthcare unit will make use of comprehensive accounts receivable services and insights, which will advance processes. Meanwhile, the patient access and, eligibility and enrollment services of Conifer integrate automation tools with personal service to upgrade efficiencies and patient experience. Thereby, revenue cycle operations of the four hospitals of Brookwood Baptist Health, which can now avail of Conifer’s innovative services suite, are expected to improve in the days ahead.Conifer has been selected by Brookwood Baptist Health to bring about improvements in revenue cycle operations across the four facilities, courtesy of Conifer’s well-established reputation as a revenue cycle solutions provider boasting of a solid presence throughout the United States.Backed by the expertise of offering revenue cycle services for over three decades, Conifer has been a preferred choice of health systems, hospitals and physician groups for partnership in tiding over revenue cycle challenges.The Conifer business was earlier supposed to undergo a spin-off with an aim to reduce the significant debt burden of Tenet Healthcare. The decision was announced in July 2019 but owing to the improved financial profiles of Conifer, THC dropped the previously made decision. Promising factors such as adjusted EBITDA margin improvement of more than 1,000 basis points at Conifer since 2017 coupled with an optimistic revenue outlook within the segment for the year 2022 have shaped Tenet Healthcare’s decision to scrap the spin-off plan. Management expects revenues within $1,325 million and $1,375 million in the segment this year, the mid-point of which indicates a 6.6% upside from the 2021 figure.The Conifer segment performed well in the first quarter of 2022. Despite the segment accounting for a small portion of Tenet Healthcare’s revenues, revenues from the same improved 4.5% year over year during the first quarter, driven by contractual rate increases and new business expansion. Similarly, initiatives similar to the latest one can be termed as one of THC’s business expansion endeavors and might boost top-line growth in the days ahead.Shares of Tenet Healthcare have lost 4% in a year compared with the industry’s decline of 11.1%. THC currently carries a Zacks Rank #3 (Hold).Image Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks in the Medical space are AMN Healthcare Services, Inc. AMN, Assertio Holdings, Inc. ASRT and Lantheus Holdings, Inc. LNTH, each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.AMN Healthcare’s earnings surpassed estimates in each of the last four quarters, the average surprise being 15.60%. The Zacks Consensus Estimate for AMN’s 2022 earnings suggests an improvement of 26.2% from the year-ago reported figure, while the same for revenues suggests growth of 23.7%. The consensus mark for AMN Healthcare’s 2022 earnings has moved north by 8.8% in the past 30 days.The bottom line of Assertio outpaced earnings estimates in two of the last four quarters and missed twice, the average surprise being 26.39%. The Zacks Consensus Estimate for ASRT’s 2022 earnings is pegged at 35 cents against the prior year’s loss of 3 cents. The same for revenues suggests growth of 16.6%. Assertio boasts of a Value Score of A.Lantheus delivered a trailing four-quarter earnings surprise of 77.82%, on average. The Zacks Consensus Estimate for LNTH’s 2022 earnings indicates a surge of 520.4% year over year, while the same for revenues suggests an improvement of 93.5%. The consensus mark for Lantheus’ 2022 earnings has moved north by 48.3% in the past 30 days.Shares of AMN Healthcare, Assertio and Lantheus have gained 4%, 55.7% and 230.3%, respectively, in a year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report Assertio Holdings, Inc. (ASRT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

NextGen Healthcare"s (NXGN) Solutions Selected by MHHC

NextGen Healthcare's (NXGN) solutions get chosen by MHHC that can help serve the latter's rapidly growing community efficiently. NextGen Healthcare, Inc. NXGN recently announced that NextGen Enterprise Electronic Health Records (EHR) and Practice Management (PM) Solutions have been chosen by Morris Heights Health Center (MHHC). This selection by MHHC — a leading NY-based Federally Qualified Health Center (FQHC) — will enable this center to serve its rapidly growing community in a better manner.It is worth mentioning that MHHC, along with its more than 120 healthcare providers, offers care and treatment to the underserved populations across New York. MHHC delivers primary, specialty, dental, behavioral health and social services throughout its health center locations.In fact, MHHC selected NextGen Enterprise to exchange patient medical records conveniently and provide all-inclusive care to its above 57,000 patients while benefiting from critical data-driven insights to enhance clinical decision-making.This announcement is likely to boost the demand for NextGen Healthcare’s solutions.More on the NewsPer management at MHHC, the collaboration with NextGen Healthcare will help the former to provide the care that the residents of the Bronx area and beyond require and deserve.Image Source: Zacks Investment ResearchPer management at NextGen Healthcare, the company’s goal is to help provide improved healthcare outcomes for all. Given the plans to extend care services across New York City, MHHC recognized the benefits of NextGen Healthcare’s solutions’ integrated functionality plus action-driven insights.Market ProspectsPer a report by Grand View Research, the global electronic health records market was estimated at $27.2 billion in 2021 and is expected to witness a CAGR of 4% from 2022 to 2030. Hence, this announcement comes at an opportune time for NextGen.Recent DevelopmentsThis month, the company collaborated with Circuit Clinical to bring clinical trial access to patients of FQHCs across over 14,000 providers that use NextGen’s solutions.In March, NextGen Healthcare announced the newest release of its NextGen Behavioral Health Suite. The suite, which builds upon the company’s NextGen Enterprise EHR and practice management system, is currently the first platform to integrate comprehensive physical, behavioral health, human services and oral health in one software solution.Price PerformanceShares of this Zacks Rank #4 (Sell) company have gained 0.7% on a year-to-date basis against the industry’s decline of 31.7%.Stocks to ConsiderSome better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Masimo Corporation MASI and Veeva Systems, Inc. VEEV.AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.6%. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.AMN Healthcare’s long-term earnings growth rate is estimated at 1.1%. The company’s earnings yield of 11.4% compares favorably with the industry’s (0.8%).Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2 (Buy).Masimo’s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company’s earnings yield is pegged at 3.8% against the industry’s (8.5%).Veeva Systems surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.6%. The company currently carries a Zacks Rank #2.Veeva Systems’ long-term earnings growth rate is estimated at 18.1%. The company’s earnings yield of 2.4% compares favorably with the industry’s 0.2%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report NEXTGEN HEALTHCARE, INC (NXGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

Masimo"s (MASI) PVi Favored by New Study for Pediatric Patients

Masimo's (MASI) PVi is expected to take better treatment decisions for pediatric patients with signs of obstructive respiratory disease in the EDs. Masimo Corporation MASI announced the findings of a favorable retrospective study in which researchers evaluated the potential ability of Masimo PVi (pleth variability index) to guide emergency room triage decisions for pediatric patients with signs of obstructive respiratory disease (such as an asthma attack or a reactive respiratory tract disease). The findings were published in the American Journal of Emergency Medicine.It is worth mentioning that PVi is a non-invasive measurement of changes in perfusion index that occur during one or more respiratory cycles.It should also be noted that the PVi is cleared as a non-invasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients in the United States.The latest positive study outcome is a stepping stone for Masimo’s patient-monitoring business across the world.Significance of the StudyPer Masimo, an acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is crucial for understanding suitable clinical treatment.The researchers noted that PVi has been shown to be a precise method for measuring the degree of pulsus paradoxus (a reduction in systolic blood pressure associated with obstructive respiratory tract disease). Hence, they aimed to understand whether PVi might be useful to ED clinicians to make rapid triage decisions in such cases.The investigators concluded that although Pulmonary Index Score is a vital tool for evaluating attack severity, it includes certain subjective parameters. Thus, automatic PVi measurement can be useful in intensive ED conditions, particularly in triage, for predicting the response of patients to treatment and follow-up results as it provides objective data. This can be achieved by rapidly determining the attack severity and reducing subjective clinical decision variations among physicians.Industry ProspectsPer a report by MarketsAndMarkets, the global patient monitoring devices market is projected to reach $55.1 billion by 2025 from $36.4 billion in 2020, seeing a CAGR of 8.6%. Factors like technological advancements and growing preference for telehealth services amid the pandemic are expected to drive the market.Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s business globally.Recent DevelopmentsThis month, Masimo announced its first-quarter 2022 financial results, wherein it reported solid top-line growth. The company also recorded robust order shipments in the reported quarter. The expansion of the company’s installed base is also impressive.In May, the company announced the limited market release of the W1 health watch for consumers. The Masimo W1 offers accurate, continuous measurements and actionable health insights in a personal, discreet, lifestyle-friendly wrist-worn wearable.In April, Masimo announced the findings of a retrospective study in which researchers investigated the impact of anesthesia during cardiac surgery guided by Masimo SedLine Brain Function Monitoring, in particular SedLine’s processed electroencephalography feature — the Patient State Index.Price PerformanceShares of Masimo have lost 34.5% in the past year compared with the industry’s 17.7% fall and the S&P 500's 6.9% decline. Image Source: Zacks Investment Research Zacks Rank & Other Key PicksCurrently, Masimo carries a Zacks Rank #2 (Buy).A few other top-ranked stocks in the broader medical space are Alkermes plc ALKS, Veeva Systems Inc. VEEV and AMN Healthcare Services, Inc. AMN.Alkermes, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 25.1%. ALKS’s earnings surpassed estimates in the trailing four quarters, the average beat being 350.5%.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Alkermes has gained 27.1% against the industry’s 38.3% fall over the past year.Veeva Systems has an estimated long-term growth rate of 18.1%. VEEV’s earnings surpassed estimates in the trailing four quarters, the average beat being 9.6%. It currently carries a Zacks Rank #2.Veeva Systems has lost 40.9% compared with the industry’s 61.5% fall over the past year.AMN Healthcare has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed estimates in the trailing four quarters, the average beat being 15.6%. It currently sports a Zacks Rank #1.AMN Healthcare has lost 0.8% compared with the industry’s 64% fall over the past year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksMay 25th, 2022

Illumina"s (ILMN) Innovations Drive Growth, Cost Woes Linger

Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline. Illumina’s ILMN market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Yet, government budget cuts, including NIH funding issues, are a major headwind. The stock currently carries a Zacks Rank #3 (Hold).llumina exited first-quarter 2022 with better-than-expected earnings and revenues. The robust year-over-year improvement in Core Illumina businesses was encouraging. Revenue contributions from the newly-formed GRAIL business, primarily from Galleri test fees, were significant. NovaSeq consumable and instrument shipments reached new highs during the quarter as the company witnessed robust demand for NextSeq 1000, 2000 from new customers. The company also saw significant growth in the installed base and a record backlog, instilling optimism. Orders for sequencing consumables surpassed $1 billion for the first time in the quarter, setting a new high for the company.Illumina is currently working on its goals to strengthen its foothold in the multi-billion gene sequencing worldwide market with some highly competitive products in its existing portfolio and pipeline. This market is developing rapidly on a global scale, leading to consistent growth in the number of non-invasive prenatal test (NIPT) samples.Within reproductive health, Illumina saw continued expansion of coverage, reimbursement and evidence generation in the first quarter of 2022, particularly in Europe. Countries such as Spain and Italy have expanded coverage for NIPT, with Germany set to follow suit later this year. In the fourth quarter of 2021, the company noted that the American College of Obstetricians and Gynecologists, or ACOG, revised its guidelines, enabling genetic testing coverage for all U.S. pregnancies, as well as increasing the adoption of its VeriSeq NIPT V2 product globally.Illumina, Inc. Price Illumina, Inc. price | Illumina, Inc. QuoteWithin genetic disease testing, Illumina registered robust first-quarter performance on expanded coverage and utilization of whole genome sequencing (WGS) globally. In April 2022, the company announced an agreement with Germany's Hannover Medical School to implement the use of WGS for critically ill children suspected of having a genetic or rare disease. In infectious disease and microbiology, the company saw a record quarter with incremental global investments in pathogen identification monitoring and resistance. This upside was driven by COVID-19 surveillance and increasing traction for other pathogens, including tuberculosis.In its oncology business, yet another area of focus in Illumina’s market expansion, this strategy led the company to develop pharma partnerships and bring to market custom panel tests.Illumina’s sequencers saw robust demand as sequencing is gradually becoming the standard of care and therapy selection. Genetic testing for therapy selection is also becoming more widely reimbursed, with more than 70% of insured lives in the United States currently covered for these tests. Further, more than 60 targeted and immunotherapy treatments are presently available on the market.On the flip side, during the first quarter, Illumina’s revenue growth across the EMEA was modestly impacted by lower shipments to Russia due to the ongoing war in Ukraine. Revenues from Greater China (which includes China, Taiwan and Hong Kong) were flat year over year as the region's robust clinical demand in hospitals was offset by COVID-19 restrictions since March.Illumina registered a significant year-over-year decline in adjusted EPS in the quarter under review, raising apprehension. The company’s research and development expenses increased 63.9% year over year, which pushed up operating costs by 10.5%. These escalating costs are building significant pressure on the bottom line.Further, in August 2021, Illumina closed the $7.1-billion impending acquisition of non-invasive, early detection liquid biopsy test provider, GRAIL. However, during the European Commission's ongoing regulatory review, the company will hold GRAIL as a separate and independent unit. Illumina is positioned to abide by the final results reached in these legal processes by keeping GRAIL separate while proceedings continue. Further, the company is dedicated to working through the continuing FTC administrative process and will follow any decision the U.S. courts reach.These regulatory complications raise the legal expenses for Illumina, thereby building pressure on the bottom line.In the past year, Illumina has underperformed its industry. The stock has lost 25.2% compared with the industry's 8.1% fall.Key PicksA few better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Medpace Holdings, Inc. MEDP and UnitedHealth Group Incorporated UNH.AMN Healthcare has a long-term earnings growth rate of 1.1%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 15.6%, on average. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.AMN Healthcare has outperformed its industry in the past year. AMN has declined 2.7% compared with the industry’s 62.4% fall.Medpace has a historical growth rate of 27.3%. Medpace’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%. It currently has a Zacks Rank #2 (Buy).Medpace has outperformed its industry in the past year. MEDP has declined 18.8% against the industry’s 62.4% fall.UnitedHealth has an estimated long-term growth rate of 14.8%. UnitedHealth’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%. It currently carries a Zacks Rank #2.UnitedHealth has outperformed the industry over the past year. UNH has gained 16.3% compared with 14% industry growth in the said period. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

Seagen (SGEN) Posts Positive Data from New Study on Tukysa

Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer. Seagen Inc. SGEN announced positive topline data from the pivotal phase II MOUNTAINEER study. The study is evaluating its oral tyrosine kinase inhibitor, Tukysa (tucatinib), in combination with Roche's RHHBY Herceptin (trastuzumab) in patients with previously-treated HER2-positive metastatic colorectal cancer (“mCRC”).The study showed that the combo of Tukysa plus Herceptin demonstrated a confirmed objective response rate of 38.1% per blinded independent central review (“BICR”). The median duration of response was 12.4 months per BICR.Also, the combo of Tukysa + Herceptin was generally safe and well-tolerated.Data from this study will support the planned supplemental new drug application (“sNDA”) for Tukysa to the FDA under its Accelerated Approval Program.Please note that pharma giant Merck MRK is commercializing Tukysa in ex-U.S markets, Canada and Europe.MRK also plans to discuss the above-mentioned data with other health authorities to accelerate the regulatory filing of Tukysa in its territory.The open-label, phase II MOUNTAINEER is investigating the combination of Tukysa plus Herceptin or as a single agent in patients with HER2-positive metastatic/unresectable colorectal cancer following previous standard-of-care therapies.Shares of Seagen have declined 9.9% so far this year compared with the industry’s fall of 23.7%.Image Source: Zacks Investment ResearchIn April 2020, the FDA approved Tukysa in combination with Roche's Herceptin and Xeloda (capecitabine) to treat adult patients with HER2-positive locally advanced or metastatic breast cancer and those who have received at least two prior anti-HER2 treatment regimens.The European Commission granted marketing authorization to the same Tukysa combo for the same indication in February 2021.In the first quarter of 2022, Tukysa generated sales worth $90.5 million, reflecting an increase of 29% on a year-over-year basis. A potential label expansion of the drug is likely to boost sales further in 2022 and beyond.Zacks Rank & Stock to ConsiderSeagen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Leap Therapeutics, Inc. LPTX, which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 over the past 60 days.Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Seagen Inc. (SGEN): Free Stock Analysis Report Leap Therapeutics, Inc. (LPTX): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksMay 25th, 2022

Thermo Fisher (TMO) to Advance Precision Medicine in Qatar

Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population. Thermo Fisher Scientific Inc. TMO recently partnered with the Qatar Genome Program (QGP), a member of the Qatar Foundation, to expedite genomic research and clinical applications of predictive genomics in Qatar. This collaboration marks a step toward extending the benefits of precision medicine to Arab populations worldwide. It supports Qatar’s national vision to provide a high standard of living for its people, including providing access to genomics data, technology and insights that enhance population health nationwide.As part of the agreement, Thermo Fisher and Qatar Genome Program will create an Axiom custom genotyping array for pan-Arab populations leveraging whole-genome sequencing data from 19 Arab countries. However, the array is currently intended for research use only and not for use in diagnostic procedures.The Axiom microarray technology is designed to advance precision medicine. This latest collaboration will likely fortify Thermo Fisher’s microarray genetic solutions business.Detailed View on Axiom ArrayWith more than 800,000 variants, the Axiom custom genotyping array seeks to drive scientific research and insights into conditions such as diabetes, cardiovascular and metabolic diseases, autism, inherited genetic disorders and cancer. Per Thermo Fisher’s management, the latest collaboration with QGP will create the building blocks for executing comprehensive precision medicine initiatives at scale for population health.Image Source: Zacks Investment ResearchThe Axiom custom genotyping array is stated to be available through Thermo Fisher’s global commercial channels during late 2022. The array, once available, is expected to deliver a cost-effective option to whole-genome sequencing for Arab populations, allowing for greater diversity in large genome-wide studies.More on the NewsIn 2018, Thermo Fisher started collaborating with QGP to create the first microarray tailored for the Qatari population. Under the new collaboration, the organizations will continue to improve algorithms and define clinically actionable content to evaluate polygenic risk scores. The content will measure disease risk and clinically relevant variants, including those associated with pharmacogenomics.Industry ProspectsPer a report by Mordor Intelligence, the genomics market is expected to see a CAGR of nearly 15.89% by 2026. Factors such as increasing government support, rising number of genomics studies, declining sequencing cost and growing genomics applications can be attributable to market growth.Given the market prospects, Thermo Fisher’s latest collaboration with QGP to utilize genomics to improve the standard of care for human health seems well-timed.Other Notable DevelopmentsIn May 2022, Thermo Fisher teamed up with biotech incubator LabShares Newton to support the Greater Boston biotech ecosystem. This collaboration aims to provide instruments, lab equipment and consumables to help early-stage life sciences companies advance their drug discovery efforts. LabShares offers fully furnished lab space, services and equipment to nearly 25 biotech companies. Under the collaboration, Thermo Fisher will add equipments like ultra-low temperature freezers, cell culture incubators, microscopes and PCR instruments to the shared lab area.In April 2022, the company opened a new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility adds to the company’s capacity to produce high-quality technology and materials for the development of vaccines and novel therapies. It is part of Thermo Fisher's $650 million multi-year investment to help ensure flexible, scalable and reliable bioprocessing production capacity for crucial materials required to develop new and existing biologics and vaccines, including for COVID-19.Share Price PerformanceThe stock has outperformed its industry in the past year. It has rallied 19.7% compared with the industry’s 16.4% fall.Zacks Rank and Key PicksCurrently, Thermo Fisher carries a Zacks Rank #3 (Hold).A few better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Medpace Holdings, Inc. MEDP and Masimo Corporation MASI.AMN Healthcare has a long-term earnings growth rate of 1.1%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 15.6%, on average. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.AMN Healthcare has outperformed its industry in the past year. AMN has declined 2.2% versus the industry’s 62.9% fall.Medpace has a historical growth rate of 27.3%. Medpace’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%. It currently has a Zacks Rank #2 (Buy).Medpace has outperformed its industry in the past year. MEDP has declined 20.4% against the industry’s 62.9% fall.Masimo has a historical growth rate of 15.1%. Masimo’s earnings beat estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2.Masimo has underperformed the industry in the past year. MASI has declined 18.2% compared with 16.1% industry drop in the said period. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

T-Mobile (TMUS) Partners Nokia, Ericsson to Launch 5G ANS

T-Mobile (TMUS) has collaborated with Nokia Corporation (NOK) and Ericsson (ERIC) to offer super-fast 5G connectivity that reduces latency by 50%. In a concerted effort to help business enterprises unlock key insights from massive data troves, T-Mobile US, Inc. TMUS has launched a suite of supercharged, managed network solutions dubbed 5G Advanced Network Solutions (ANS). The company has collaborated with leading communication equipment vendors like Nokia Corporation NOK and Ericsson ERIC in this endeavor to offer superfast 5G connectivity that reduces latency by 50%.Leveraging its industry-leading 5G network and spectrum for ANS, T-Mobile aims to provide three distinct 5G advanced network options for business enterprises that break away from the one-size-fits-all, costly and complex 5G Private Networks. These include Public Mobile Network, a Hybrid Mobile Network and a Private Mobile Network with the choice to add compute to each option or use one’s own compute provider.The T-Mobile Public Network offers a faster download speed compared to legacy networks. This high-speed lower latency network utilizes such a path trajectory that data needs to travel less distance from the device to the compute resource and back. The Hybrid Mobile Network is comparatively faster than the Public Network and is ideal for immersive VR training, computer vision and inspections and other data-intensive applications. The Private Mobile Network is the fastest of the lot and is mostly needed for demanding applications, like industrial automation in a factory or fully autonomous robots.In order to realize these network speeds of ANS, T-Mobile intends to utilize Nokia’s Digital Automation Cloud Private Network solution and related equipment. Nokia is driving the transition of global enterprises into smart virtual networks by creating a single network for all services, converging mobile and fixed broadband, IP routing and optical networks with the software and services to manage them. It is transforming the way people and things communicate and connect with each other through a seamless transition to 5G technology, ultra-broadband access, IP and Software Defined Networking, cloud applications and IoT.The company facilitates its customers to move away from an economy-of-scale network operating model to demand-driven operations by offering easy programmability and flexible automation to support dynamic operations, reduce complexity and improve efficiency. Nokia remains focused on building a robust, scalable software business and expanding it to structurally attractive enterprise adjacencies. The company’s end-to-end portfolio includes products and services for every part of a network, which are helping operators to enable key 5G capabilities, such as network slicing, distributed cloud and industrial IoT. Accelerated strategy execution, sharpened customer focus and reduced long-term costs are expected to position the company as a global leader in delivering end-to-end 5G solutions.T-Mobile also seeks to offer superfast 5G network connectivity by leveraging ERIC’s communications equipment. Ericsson is focusing on 5G system development and has undertaken many notable endeavors to position itself for market leadership on 5G. The company believes that the standardization of 5G is the cornerstone for digitizing industries and broadband. Ericsson foresees mainstream 4G offerings giving way to 5G technology in the future. The deployment of 5G networks is expected to boost the adoption of IoT devices, with technologies like network slicing gaining more prominence. The company is reportedly the world’s largest supplier of LTE technology with a significant market share and has established a large number of LTE networks worldwide.With the help of such state-of-the-art equipment and an extensive 5G network of its own, T-Mobile aims to seamlessly transfer 5G data to business enterprises and strengthen its position as a leading service provider in the country.The stock has lost 5% over the past year against the industry’s decline of 17%. We remain impressed with the inherent growth potential of this Zacks Rank #3 (Hold) stock.Image Source: Zacks Investment ResearchA better-ranked stock in the broader industry is Clearfield, Inc. CLFD, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Clearfield delivered an earnings surprise of 37.5%, on average, in the trailing four quarters. Earnings estimates for the current year for the stock have moved up 114.7% since May 2021. Over the past year, Clearfield has gained a solid 60.9%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ericsson (ERIC): Free Stock Analysis Report Nokia Corporation (NOK): Free Stock Analysis Report TMobile US, Inc. (TMUS): Free Stock Analysis Report Clearfield, Inc. (CLFD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

S&P Global (SPGI) Gains From Acquisitions Despite High Debt

S&P Global's (SPGI) acquisition strategy to innovate, increase differentiated content and develop new products looks impressive. S&P Global, Inc. SPGI is currently benefiting from contributions from acquisitions and strength across every segment, except the Ratings division.SPGI recently reported  lower-than-expected first-quarter 2022 results. Adjusted earnings per share (excluding $1.58 from non-recurring items) of $2.89 missed the consensus mark by 3.7% and decreased 14.8% year over year. Revenues of $2.39 billion missed the consensus estimate by 15.7% but improved 18.5% year over year.S&P Global Inc. Price S&P Global Inc. price | S&P Global Inc. QuoteHow is S&P Global Doing?Acquisitions act as a key growth catalyst for S&P Global, helping it continuously innovate, increase differentiated content and develop new products. On Feb 28, 2022, SPGI announced the completion of its merger with IHS Markit. The buyout is expected to enhance SPGI’s data and analytics offerings. It is anticipated to be accretive to its earnings by the end of the second year post closure. On Jan 4, 2022, S&P Global announced that it completed the acquisition of The Climate Service.  The deal is expected to enhance SPGI's portfolio of essential environmental, social, and governance (ESG) insights and solutions’ capabilities. This should help it modify its climate data, models and analytics-related offerings. In 2020, S&P Global completed the acquisitions of ESG Ratings Business (from RobecoSAM) and Greenwich Associates LLC. While ESG Ratings Business will boost SPGI’s position as a premier resource for the essential ESG data, ratings, benchmarks and insights, Greenwich will complement its existing portfolio of products and expand its offerings to new segments across financial services, including commercial banks, and asset and wealth managers. Going ahead, we expect S&P Global to continue adding its advanced technology and data sets through acquisitions, which in turn, should boost its top- and the bottom line.S&P Global’s cash, cash equivalents and restricted cash of $4.40 billion at the end of first-quarter 2022 was well below its long-term debt of $11.33 billion. Further, SPGI’s current ratio (a measure of liquidity) at the end of the reported quarter was pegged at 1.38, lower than the current ratio of 2.31 reported at the end of fourth-quarter 2021 and the prior-year quarter’s 1.85. Decreasing current ratio is not desirable as it indicates possible problems in meeting the short-term debt obligations.Zacks Rank and Stocks to ConsiderS&P Global currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Some better-ranked stocks in the broader Business Services sector that investors can consider are Cross Country Healthcare CCRN, Gartner IT and Avis Budget CAR, each carrying a Zacks Rank #1 at present.Cross Country Healthcare has an expected earnings growth rate of 49.4% for the current year. CCRN has a trailing four-quarter earnings surprise of 29.2%, on average.Cross Country Healthcare has a long-term earnings growth rate of 6.9%.Gartner’s shares have risen 5.6% in the past year. IT delivered a trailing four-quarter earnings surprise of 24.2%, on average.The Zacks Consensus Estimate for Gartner's earnings in the current year has moved up 9.8% in the past 90 days.Avis Budget has an expected earnings growth rate of 59.8% for the current year. CAR delivered a trailing four-quarter earnings surprise of 102.1%, on average.Avis Budget has a long-term earnings growth rate of 19.4%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Avis Budget Group, Inc. (CAR): Free Stock Analysis Report Gartner, Inc. (IT): Free Stock Analysis Report Cross Country Healthcare, Inc. (CCRN): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 25th, 2022

Brian Moynihan: People Have Not Spent Down Their Stimulus Money Yet

Following is the unofficial transcript of a CNBC interview with Bank of America Corp (NYSE:BAC) Chairman & CEO Brian Moynihan on CNBC’s “Squawk Box” (M-F, 6AM-9AM ET) today, Monday, May 23rd for Davos 2022 in Davos, Switzerland. Following is a link to video on CNBC.com: Bank Of America CEO Brian Moynihan: People Have Not Spent […] Following is the unofficial transcript of a CNBC interview with Bank of America Corp (NYSE:BAC) Chairman & CEO Brian Moynihan on CNBC’s “Squawk Box” (M-F, 6AM-9AM ET) today, Monday, May 23rd for Davos 2022 in Davos, Switzerland. Following is a link to video on CNBC.com: Bank Of America CEO Brian Moynihan: People Have Not Spent Down Their Stimulus Money Yet ANDREW ROSS SORKIN: Lots of folks making their way here. A little bit different than in the past, but I think we’re gonna get some insights into what’s going on in the economy around the globe. Lots of concerns, of course, about inflation, about Ukraine, Russia, this news this morning that President commented on with Taiwan already making its way around. President Zelenskyy kicked off the Davos session this morning, piping in from Ukraine this morning. But nonetheless, as we said, we’ve got Brian Moynihan in just a moment but we have so many others joining us but we have Brian on the set with us as we speak so why don’t we get right to him and begin this conversation, get the mood of what’s really happening here. Brian, it’s nice to see you. if (typeof jQuery == 'undefined') { document.write(''); } .first{clear:both;margin-left:0}.one-third{width:31.034482758621%;float:left;margin-left:3.448275862069%}.two-thirds{width:65.51724137931%;float:left}form.ebook-styles .af-element input{border:0;border-radius:0;padding:8px}form.ebook-styles .af-element{width:220px;float:left}form.ebook-styles .af-element.buttonContainer{width:115px;float:left;margin-left: 6px;}form.ebook-styles .af-element.buttonContainer input.submit{width:115px;padding:10px 6px 8px;text-transform:uppercase;border-radius:0;border:0;font-size:15px}form.ebook-styles .af-body.af-standards input.submit{width:115px}form.ebook-styles .af-element.privacyPolicy{width:100%;font-size:12px;margin:10px auto 0}form.ebook-styles .af-element.privacyPolicy p{font-size:11px;margin-bottom:0}form.ebook-styles .af-body input.text{height:40px;padding:2px 10px !important} form.ebook-styles .error, form.ebook-styles #error { color:#d00; } form.ebook-styles .formfields h1, form.ebook-styles .formfields #mg-logo, form.ebook-styles .formfields #mg-footer { display: none; } form.ebook-styles .formfields { font-size: 12px; } form.ebook-styles .formfields p { margin: 4px 0; } Get The Full Henry Singleton Series in PDF Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues (function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';}(jQuery));var $mcj = jQuery.noConflict(true); Q1 2022 hedge fund letters, conferences and more BRIAN MOYNIHAN: It’s good to see you, Andrew. It's a beautiful setting and you can hear the bells. SORKIN: It's windy, it's windy and things may go down. That's the only thing we should worry about. I've already been to one dinner. There seems to be, I hate to say it, a lot of pessimism, a lot of sense that inflation is not transitory and that this is going to be extended and prolonged. What are you seeing in the last couple of weeks in terms of at the bank, in terms of bank account balances, what are you seeing now? MOYNIHAN: Well, what we're seeing is, more importantly, the balances are balances continue to be stable and continue to grow year over year for the broad base of consumers. More importantly, the spending levels in May for the first few weeks are up 10% last May, and that is not as high as it would otherwise be because last May people pay taxes so it actually it’s a bigger base to grow from so year to date, they’re up 17% fairly standard in May they’re up 17%, the consumers continue to spend in the balances of our customers, they have more money in April, their balances grew up in March and March they grew over all the way back to mid last year. So the notion that people are spending the stimulus down isn't happening yet. It may happen but it hasn’t happened yet. SORKIN: Right so I was gonna say you we hear anecdotal reports. Here's some high frequency folks who are looking at things who have tried to suggest the last two or three weeks bank balances have started instead of rising to start to come down. Is that not the case? MOYNIHAN: It'll happen because people paying their taxes and so the reason why California has big surplus, a lot of taxes we pay in the US governments haven't been received so you're seeing especially among affluent customer frankly than the broader customers, people paying a lot of taxes and that happened in April. You saw the balances go down a little bit but that's the normal pattern year to year people will overread that and not really understand it. Every year, this quarter because in the month of April we all, everyone sends a bunch of money to the government and government survives off it and does good things with it. But that's that's what's happening. Generally stated though, if you compare this April to last April, it's up 8%. This May, the last May, is still up 8%. SORKIN: The other data point that you always have for us though is mortgages. What are you seeing there in terms of people's interest or people starting to pull back a little? MOYNIHAN: Well, mortgages have slowed down because frankly, the refi thing drops away right and so Americans just put out a paper the other day and what people have to realize about mortgages is all the fixed rate mortgages which are the dominant dominant part of them, don't change rates because rates go up. What the impact is on future mortgages so when people buy a house, will they be able to buy as big of a house. The reality is 200 basis point mortgage rise on a $300,000 house is $500 a month. The question is if you make 100,000, you got 6% income rise, it's the same amount of money and so what's different than this time when the raise rates rose in the 17, 18, 19 framework is that wages are rising three times what they're rising back then so people can keep up with. It's gonna be interesting, right now they slowed down all on a refi. The house purchases are still going through. SORKIN: So all this says what to you about this larger conversation that's having that we're having now about our economy. MOYNIHAN: So there's a lot of fear and worry about the Fed tightening in the federal slowdown in the economy. That is what they're going to do. And so our economists have this year predicted, everybody keeps moving, as the Fed has said they're gonna raise rates faster, everybody keeps moving their estimates down. Our economists said Friday there's a 1/3 chance of recession, those numbers get overquoted. If you'd asked them in the middle of ‘17, ‘18, they’d have said there’s a 15% to 20% chance of recession but nobody had it on their mind. The reality is, it's moved up. It's moved up because the government has to slow down and take on inflation. Inflation, you said transitory, it wasn't transitory last fall and that's when everybody was figuring it out. Now, they've got to move fast. They moved 50 last meeting they expect to move 50 two meetings. That is an unprecedent fast rate. The question is could they slow it down without tipping over? And that's what the debate is about. People get up in the morning, one side of the bed says it’s going to tip over people on the other side of the bed said we'll be fine. Our team believes we’ll grow this year and next year. And by the way, if you look at all the blue chip economists only one out of like 40 economists has a negative number this year, and nobody has one next year. And if you look at all the big firms, none of them have the negative quarters. So something is this the probability is rising, the fear is going up. But the reality is, is no one's really saying there'll be a recession in ’22 or ’23 yet. We’ll see what happens there. SORKIN: What’s Brian Moynihan saying? MOYNIHAN: We think the economy will slow down. But with this kind of spending and this kind of activity, the Fed has a tough job in this kind of employment tightness, the Fed has a tough job, but it's a job they have to they're getting after much faster than before and we'll have to see if they can get the balance right. SORKIN: Becky’s got a question back back in New York. Becks? BECKY QUICK: Hey, thanks Andrew. Brian, I see today that you are raising your minimum wage to $22 from the $21 it had been. This all kind of plays into it. People are having a tougher time keeping up with the costs that are rising everything from gasoline prices to food prices and it's great to see that but it also comes into this whole wage inflation spiral that that you see what's what's going on. Why do you feel the need to raise wages? What does this mean for your employee base, and then how does that kind of fit into the broader picture of inflation too? MOYNIHAN: So Becky today we announced, we had a pattern going from we announced from ‘20 to ’25, in the year of ’20 to ’25, a dollar each year, we moved it up and announced today to from what was gonna be October to June. But importantly, last week, we also announced for everybody making less 100,000 in our company, we increased our wages by 3%, 5%, 7% based on the years of service, so what we're really trying to do is say we need the best team to serve our clients and we're trying to make sure that we make make our teammates feel great about working at our company so with a $22 hour start wage, it's fairly straightforward. You get $45,000 a year if you're an individual, you pay about $100 a month for full medical care, you get a 7% dollar for dollar employer match, and $10,000 tuition reimbursement, if you have children $275 per child per month. These are all benefits because we want our team to be able to focus on their career here and stay with a company a long time and so we've raised in response to some pressures we've raised and we've hired 7,000 people in the first quarter. We aren’t having trouble hiring people, but it's really to make sure we stabilize and have the best team that we can have. QUICK: I mean that's fantastic and it definitely means good things for your team. I just tried to get to the broader issue of what this might mean and what it's going to take for people to be able to I mean real wages are dropping overall if you look at the numbers, the the inflationary pressures from CPI are eating away at any of the wage gains that people have gotten on average, not from your company, but on average. What what do you think about this? Does it concern you to watch that? MOYNIHAN: Well, that's that's the that's the question. So the labor market is tight and you're hearing stories about, you know, our turnover moved up to where it was in ‘19 and about a little bit higher and still well within what lower was like in ‘17 so we feel good about it. But the reality is when I talk to CEOs around the country getting people is number one issue. Labor market’s tight, there's two job openings for every job. Go into some of that real time data we've seen in one of our real time data sets a little less job postings, which may mean the markets easing but until that labor market eases the weight of wage growth is going to be strong and then the question is can they slow price appreciation in light of wage growth carries through for real wage growth. And that's, that's getting, especially with the market being down because it’s helped broadly people’s 401(k)s that create things these are all impacts on people's view. The reality though is they are changing their behavior as of last week, in other words, travel in the month of May up 40% over last year. Restaurants up are they spending less at retail goods? Yeah, it's flattish a little bit. But they're spending the money on experiences and doing things. So that's the conundrum and that's because frankly, a lot of them have the stimulus from before so the real pressure point here I think would be as we move to the fall unless you see some ease in the price appreciation and stabilization. So gas prices stabilized at some level, you know, and other things that people, grocery prices stabilized then I think people really will get much more concerned right now it's competitive out there as people are raising wages. SORKIN: But there's still stimulus, meaning that you think that a lot of these bank accounts still have some of that stimulus money and that— MOYNIHAN: So for our account holders in April, if you had if they had between $1,000 and $2,000, before the pandemic they had an average balance of $1,400 they had about $4,000 in April. If they had an average balance of $2,000 to $5,000 pre pandemic, they would carry about $35,000, they would carry $13,000 in balances. They haven’t spent them down yet and they grew 5% from March to April. This is— SORKIN: That’s a remarkable statistic. MOYNIHAN: Remember, we have 35 million checking customers so I'm not giving you a little tiny sample. I'm giving you a sample of a broad base of households in America. So what you're, and they’re all primary accounts and you’ve been seeing to Becky's point in our employment checks deposited, you know, our customers getting their, not our people, but other people you’re seeing their wages have grown 8% year over year. And so when you look at all that, that stimulus, the notion people start spending down, it’s been growing every month since last July. Will they spend it down? Probably but not right now. SORKIN: Another sort of Davosian question, always a big conversation here about ESG and lots of pledges have been made climate pledges and other things over the years here. Question is whether that is a sort of that was a something that happened during a boom times and what happens in a challenged economy meaning all these companies that said we're gonna do this, this and this over the next 5, 10 years, we're gonna spend billions of dollars. Do you think that that changes do you think they say, you know what, actually I can't do that or activists are calling up and saying, no you cannot just get, you gotta cut this stuff out. MOYNIHAN: So I think we believe at Bank of America it’s profits and purpose, not or. SORKIN: No I know— MOYNIHAN: And the key to that is we have to produce on earnings $7 billion in the first quarter and record earnings last year and we have to produce so when you think about it more broadly, think of the environmental commitments. We made our first environment commitment 2004. You think we went through some interesting times between 2004 and today and it went from 25 billion to 50 billion to 125 billion to 350 and now a trillion all financing our client’s transition. So what I think Andrew is more people will ebb and flow on this given the pace of things, the fear about energy drives more activity. Well, maybe other things. The reality is if people have done it right in a World Economic Forum here at the International Business Council which I chair has had these metrics we put out, 140 companies have signed on them. 72 are under second year disclosing all those laid out bear if you're not making progress, and people can see it. So whether it's whether it's women on boards, or whether it's diversity overall, or whether it's progress on environmental commitments, I think people will stick to them because they've aligned capitalism to achieving the goal. And by the way, these goals will not be achieved without the private sector doing it. The government doesn't have the money. SORKIN: But let me ask you, you were very ambitious around climate and specifically on fossil fuels, right? In terms of what what fossil fuel companies you would finance, what kind of projects you would finance. In this environment now where gas costs as much as it does and people look around and there's a question, was this the right call. MOYNIHAN: We finance oil and gas companies and we finance the green companies and sometimes it's the same company. You know, that's the interesting thing is even the oil companies have made major commitments to change some of that cash flow. Is it the right call? In a spot base, you’d say we wish we had more oil and you're seeing the production, the wells are coming up and the production starting to pick up here in the US and the Middle East and stuff and that will happen because the demand will be there and the price will be there, of course people are going to, this is a transition. We have to have energy for everybody. We have to have all kinds of energy, we have to build it. Meanwhile, we did $250 billion in financing last year. So during the pandemic kept growing, it will do that much or more this year. And so our clients have made and this is, what they say it’s a markets initiative, I work with we've we just had a meeting in London a couple of weeks ago, 100 CEOs in a room all have commitments, all driving is part of how they're driving their business. It's not some commitment. It's not charity. That's what, when people turned the switch from charity, which which is terrific and wonderful but doesn't give you enough money to aligning the business when they make a purchase commitment for sustainable aviation fuels, a purchase commitment for clean energy, or in our case, our commitment over multiple years to drive down our energy, our commitment will to build a power, all these are commitments that are gone. I mean, they're going on it's not like you reverse them because they're already working. SORKIN: Becks? QUICK: Brian, real quickly. Let's go back to the job market again. You mentioned that this is a situation where you think the job market could be easing a little bit not not quite as tight as it has been based on what you see with job postings. I mean it's been an employee's market for so long this has been a take, take your job and shove it market. Do you think that that is going to switch soon or how do you read that? What kind of other things are you watching to see on that front? MOYNIHAN: It's not gonna switch soon. So if you look at all those economists including ours, they still have the unemployment rate barely getting to 4% or maybe 3.5%, 3.6% at the end of next year. It's still going to be a very tight labor market, frankly, because in the US because we don't have, you know, we aren't getting more people and now, all the most of the workforces that pre-pandemic were at X are all back at workforce except for young people. So we got to pull them off the side, it’s the optimists say, we can pull more people in and that participation rate will go up and employment the population rate will go up and you're seeing some signs of that. Older people who said retired, wouldn’t come back. They did. They’re back at the same levels they were before older workers so there's optimism there. But frankly, that's one of the challenges the Fed has is the unemployment rate is projected by everybody be very tight in historical context and that then would make their job tougher because that wage inflation will be harder to tame. Goods, inflation may come down faster but wage inflation is gonna be a tough nut. SORKIN: Hey Joe. JOE KERNEN: Yeah Brian, thanks Andrew. Back to the ESG issue again and in light of what we're seeing with with some of the pushback against Larry Fink and maybe some of the other big money managers, managers that are voting shares from their own preferences it seems like some of their own causes. I don't know if it's that much different for a CEO that might steer the company, your company, for example, in a direction that he has a personal opinion on. And I'm just wondering, did you ever worry about that you're talking about a transition to clean energy, which may or may not have hindered financing for fossil fuel, for the fossil fuel industry in the United States. Now, you know, that's coming home to roost, obviously, where do you draw the line? Do you cut of gun makers, do you get involved with voting rights issues? These are all your own opinions as CEO, but it doesn't seem much different than what Larry Fink does, which is receiving a lot of pushback now. Should a, should a CEO be able to steer his company in a manner that that follows his politics? MOYNIHAN: Well, I don't follow my politics because most of you wouldn't even know what they were and the company wouldn't know it. So we have, we have 200,000 people and they represent every interest so we tend to take action when it means something to our teammates, but on the energy thing, I get a letter one day from people saying we're financing fossil fuels and we did underwriting for oil and gas companies. I get a letter the next day saying the opposite, you're cutting them off, and I went out with Senator Cramer out to to Fargo, North Dakota and talked to him about that that state has declared to be net zero by 2030 or ‘40 or something like that. They're building these huge carbon capture storage facilities. We're working with people in that to drive it back so there's gonna be a lot of competing ideas and competing things here. But the reality is we drive profits and purpose Joe, and that's how we run the company. And I'd simply say, if we did things that were good for our customers, you'd say that's fine. If you did things that were good for our teammates, you'd say that's fine. If you did things that were good for our shareholders, you’d say that's fine. If we did things that were good for our communities of which a bank depends on its communities to be successful to have customers, you’d say that’s fine. That's what we do and I don't think that's an unusual idea. It's an idea which has been around for a long time and it's it's, I did my first strategic plan laid out that way for a company in 1993 or 1994 or something like that. These are not new ideas. So I think the politics are completely different from actually driving the company for what society what's what society does, needs and how capitalism can help drive the right things for things that are economic based, are teammate based, and things like that and customer based and shareholder based. And that’s what we do, profits and purpose. Not or, and you can read my shareholder letter, I lay it out and I think our shareholders are backing it. SORKIN: Brian, before we let you go, gotta ask this is a topic that everybody seems to be talking about Elon Musk. You guys are actually backing the margin loan that's going to allow him to either buy Twitter or not. MOYNIHAN: You keep asking people that and they all say the same thing, it’s not our deal. You have to talk to the principals to figure out what’s going on. SORKIN: You think it’s gonna happen? MOYNIHAN: You have to talk— SORKIN: Let me ask you one other question related though. No, but here's here's this is a fascinating question. Margin loans. There's a big question about whether billionaires or anybody of great wealth should be able to use a loan that is not taxed, and still create effectively that value. I don't know if you saw Trevor Noah created a sort of viral video about this sort of goes to wealth tax, and whether effectively, money that we say is not really being used in any real way because it's not available actually does become available through a margin loan in this kind of context. What do you think about that? MOYNIHAN: Well, a couple of things. One is there's that that's the way the rules are, you can have a margin loan, Joe can have a margin loan, you can have a brokers account and borrow up to 50 cents on the dollar. That's what's given. So I think it's in for a penny, in for a pound, either everybody can do it or not. The second thing is that money is used to do something that generates taxes, we pay taxes on the interest we get on those loans. And so I think it's a much more complex question someone might understand just saying I borrow money and not pay taxes because taxes are paid by other participants, the underlying assets they buy have taxes, if there's dividends, that's taxed on a flow basis. Having been a lawyer a long time ago and steady taxation, it's much more complex than the average person thinks. SORKIN: Thank you, counselor. Appreciate it. Brian Moynihan, thank you very, very much. Updated on May 23, 2022, 9:57 am (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkMay 23rd, 2022

So-Young Reports Unaudited First Quarter 2022 Financial Results

BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- So-Young International Inc. (NASDAQ:SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Highlights Total revenues were RMB300.3 million (US$47.4 million1), a decrease of 16.5% from RMB359.6 million in the same period of 2021, exceeding the high end of our previous guidance. Net loss attributable to So-Young International Inc. was RMB66.8 million (US$10.5 million), compared with net loss attributable to So-Young International Inc. of RMB45.0 million in the first quarter of 2021. Non-GAAP net loss attributable to So-Young International Inc.2 was RMB48.3 million (US$7.6 million), compared with non-GAAP net loss attributable to So-Young International Inc. of RMB26.1 million in the same period of 2021. First Quarter 2022 Operational Highlights Average mobile MAUs were 4.4 million, compared with 8.4 million in the first quarter of 2021. Number of paying medical service providers on So-Young's platform were 5,254, an increase of 11.7% from 4,702 in the first quarter of 2021. Number of medical service providers subscribing to information services on So-Young's platform were 1,891, compared with 2,191 in the first quarter of 2021. Total number of users purchasing reservation services were 120.4 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB341.5 million. Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "We started the new fiscal year by delivering solid results amid the resurgence of COVID-19 cases across cities in China and the challenging macro environment. We further optimized community content and online infrastructure capacity through technology and innovation to improve user experience and branding digital support for medical service providers. As a result, the number of paying medical service providers on our platform were 5,254 in the first quarter of 2022, up 11.7% from 4,702 year-over-year." Mr. Jin continued, "During the quarter, we made some short videos on user experience of non-surgical products to increase user trust and user engagement. Meanwhile, we continued to build So-Young authentic product in non-surgical business to acquire consumer awareness. Going forward, we will continue to expand product offerings, improve service quality, innovate our content, and bring new value to reaffirm our leadership position." Mr. Min Yu, "Our growing consumer awareness helped drive the solid results for the quarter amid macro challenges. With sustained user trust and improving acquisition efficiency for medical service providers across our platform, we have continued our revenue and strong cash position that enable us to invest new business in long-term growth. Looking ahead, we are confident of our growth prospects and generate long-term value for our shareholders." First Quarter 2022 Financial Results Revenues Total revenues were RMB300.3 million (US$47.4 million), a decrease of 16.5% from RMB359.6 million in the same period of 2021. The decrease was primarily due to a decrease in average revenue per paying medical service provider which was impacted from the resurgence of COVID-19. Information services and other revenues were RMB199.5 million (US$31.5 million), a decrease of 28.2% from RMB277.8 million in the same period of 2021. The decrease was primarily due to a decrease in average revenue per paying medical service provider subscribing to information services. Reservation services revenues were RMB42.4 million (US$6.7 million), a decrease of 48.2% from RMB81.8 million in the same period of 2021. The decrease was primarily due to the impact from the resurgence of COVID-19 across the country and adoption of new operating strategy which gave higher subsidies to end users. Sales of equipment and maintenance services revenues were RMB58.5 million (US$9.2 million), from Wuhan Miracle. Cost of Revenues Cost of revenues were RMB106.6 million (US$16.8 million), an increase of 103.6% from RMB52.4 million in the first quarter of 2021. The increase was primarily due to the consolidation of the costs of Wuhan Miracle. Cost of revenues included share-based compensation expenses of RMB2.6 million (US$0.4 million) during the first quarter of 2022, compared with RMB4.3 million in the corresponding period of 2021. Operating Expenses Total operating expenses were RMB271.5 million (US$42.8 million), a decrease of 26.1% from RMB367.3 million in the first quarter of 2021. Sales and marketing expenses were RMB127.2 million (US$20.1 million), a decrease of 47.5% from RMB242.4 million in the first quarter of 2021. The decrease was primarily due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses for the first quarter of 2022 included share-based compensation expenses of RMB3.4 million (US$0.5 million), compared with RMB2.3 million in the corresponding period of 2021. General and administrative expenses were RMB65.4 million (US$10.3 million), an increase of 18.5% from RMB55.2 million in the first quarter of 2021. The increase was primarily due to the consolidation of Wuhan Miracle and the increase of payroll costs. General and administrative expenses for the first quarter of 2022 included share-based compensation expenses of RMB7.9 million (US$1.2 million), compared with RMB7.2 million in the corresponding period of 2021. Research and development expenses were RMB78.9 million (US$12.5 million), an increase of 13.1% from RMB69.8 million in the first quarter of 2021. The increase was primarily attributable to an increase in payroll costs. Research and development expenses for the first quarter of 2022 included share-based compensation expenses of RMB4.6 million (US$0.7 million), compared with RMB5.1 million in the corresponding period of 2021. Income Tax Benefit/(Expenses)Income tax benefit were RMB2.0 million (US$0.3 million), compared with income tax benefit RMB4.3 million in the same period of 2021. Net loss attributable to So-Young International Inc. Net loss attributable to So-Young International Inc. was RMB66.8 million (US$10.5 million), compared with a net loss attributable to So-Young International Inc. of RMB45.0 million in the first quarter of 2021. Non-GAAP net (loss)/income attributable to So-Young International Inc. Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB48.3 million (US$7.6 million), compared with RMB26.1 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2021. Basic and Diluted Loss per ADS Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.62 (US$0.10) and RMB0.62 (US$0.10), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.42 and RMB0.42, respectively, in the same period of 2021. Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments As of March 31, 2022, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,693.1 million (US$267.1 million), compared with RMB1,756.0 million as of December 31, 2021. Business Outlook As a result of the uncertainties created by the on-going COVID resurgence in China, we are unable to give revenue guidance for the second quarter of 2022. Non-GAAP Financial Measures To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP (loss)/income from operations and non-GAAP net (loss)/income attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and intangible assets from (loss)/income from operations and net (loss)/income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. The impairment of goodwill and intangible assets are non-cash in nature. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses and impairment of goodwill and intangible assets in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release. About So-Young International Inc.So-Young International Inc. (NASDAQ:SY) ("So-Young" or the "Company") is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market. Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to fourth parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young's business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law. For more information, please contact: So-Young Investor RelationsMs. Vivian XuPhone: +86-10-8790-2012E-mail: ir@soyoung.com Christensen In ChinaMr. Eric YuanPhone: +86-10-5900-1548E-mail: Eyuan@christensenir.com In USMs. Linda BergkampPhone: +1-480-614-3004Email: lbergkamp@christensenir.com SO-YOUNG INTERNATIONAL INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands, except for share and per share data)   As of   December 31,   March 31,   March 31, 2021 2022 2022   RMB   RMB   US$ Assets           Current assets:           Cash and cash equivalents 1,331,968   1,564,352   246,770 Restricted cash and term deposits 15,119   17,922   2,827 Trade receivables 54,829   42,126   6,645 Inventories, net 91,812   89,065   14,050 Receivables from online payment platforms 18,864   17,225   2,717 Amounts due from related parties 14,038   28,139   4,439 Term deposits and short-term investments 408,946   110,854   17,487 Prepayment and other current assets 91,842   83,791   13,218 Total current assets 2,027,418   1,953,474   308,153 Non-current assets:           Long-term investments 252,500   251,398   39,657 Intangible assets 193,955   187,818   29,628 Goodwill 540,693   540,693   85,292 Property and equipment, net 124,576   122,779   19,368 Deferred tax assets 47,520   47,524   7,497 Operating lease right-of-use assets 95,609   88,813   14,010 Other non-current assets 48,097   57,694   9,101 Total non-current assets 1,302,950   1,296,719   204,553 Total assets 3,330,368   3,250,193   512,706             Liabilities           Current liabilities:           Taxes payable 48,571   50,250   7,927 Contract liabilities 139,155   139,321   21,977 Salary and welfare payables 103,624   73,442   11,585 Amounts due to related parties 681   57   9 Accrued expenses and other current liabilities 376,841   385,434   60,801 Operating lease liabilities-current 43,529   48,115   7,590 Total current liabilities 712,401   696,619   109,889 Non-current liabilities:           Operating lease liabilities-non current 62,356   52,496   8,281 Deferred tax liabilities 38,577   36,770   5,800 Total non-current liabilities 100,933   89,266   14,081 Total liabilities 813,334   785,885   123,970             SO-YOUNG INTERNATIONAL INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands, except for share and per share data) Shareholders' equity:           Treasury stock (217,712 )  .....»»

Category: earningsSource: benzingaMay 23rd, 2022

Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY"s Tirzepatide

FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide). This week, the FDA granted emergency authorization to booster shots of Pfizer PFE/BioNTech’s COVID-19 vaccine for use in children 5 to 11 years of age and also approved Lilly’s LLY novel diabetes treatment, Mounjaro (tirzepatide) injection. AbbVie ABBV and AstraZeneca AZN announced new licensing deals with small private biotechs.Recap of the Week’s Most Important StoriesFDA Approves Lilly’s Novel Diabetes Treatment: The FDA approved Lilly’s dual GIP and GLP-1 receptor agonist, Mounjaro (tirzepatide) injection for treating type II diabetes. Mounjaro is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies. Mounjaro will be available in six doses as an auto-injector pen. It is expected to be launched in the United States in the next few weeks.FDA Gives Emergency Nod to Pfizer’s COVID Jab for Kids 5-11: The FDA granted emergency use authorization (EUA) to a booster/third dose of Pfizer/BioNTech’s mRNA-based COVID-19 vaccine, Comirnaty for children aged between 5 years and 11 years. The expanded EUA to include a booster dose for children was based on data from a phase II/III study, which showed a 36-fold increase in neutralizing antibodies against the Omicron variant in children who were given the booster dose. A booster dose of Comirnaty is already authorized for all adults and adolescents aged 12 years to 15 years while a second booster dose or “fourth” dose is authorized for older adults and some immunocompromised individuals. Comirnaty is the only COVID-19 vaccine with a EUA for use in children as primary series as well as for a third dose.AbbVie Buys Option Rights to Novel Inflammation Candidate: AbbVie received an option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from precision medicines biotech, Cugene. CUG252 is being evaluated in a phase I study in healthy volunteers while Cugene plans to conduct a phase Ib study in patients with autoimmune/inflammatory disease during the option period. For the deal, AbbVie will make an upfront payment of $48.5 million to Cugene while also being entitled to make future development and regulatory milestone payments. If AbbVie chooses to exercise the option, it will have to make an option exercise payment and will then take care of all future clinical development and commercialization activities related to CUG252.AstraZeneca Buys Rights to COVID Antibody: AstraZeneca acquired an exclusive worldwide licence from London-based private biotech, RQ Biotechnology Ltd to develop and market monoclonal antibodies (mAbs) against the COVID-19 virus, SARS-CoV-2. For the rights, RQ Bio will receive upfront and milestone payments of up to $157 million while also being eligible for single-digit royalties on future sales of mAbs.AstraZeneca’s cocktail mAb, Evusheld, a combination of two long-acting antibodies, tixagevimab and cilgavimab, is already authorized for pre-exposure prophylaxis (prevention) of COVID-19.The NYSE ARCA Pharmaceutical Index rose 0.7% in the last five trading sessions.Large Cap Pharmaceuticals Industry 5YR % Return Large Cap Pharmaceuticals Industry 5YR % ReturnHere’s how the eight major stocks performed in the last five trading sessions.Image Source: Zacks Investment ResearchIn the last five trading sessions, AstraZeneca rose the most (5%) while J&J declined the most (2.2%).In the past six months, AbbVie rose the most (31.2%) while Roche declined the most (16.7%).(See the last pharma stock roundup here: PFE’s Biohaven Buyout Offer, BAYRY’s Q1 Earnings Update)What's Next in the Pharma World?Watch for regular pipeline and regulatory updates next week. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksMay 20th, 2022

Will Healthy Revenue Growth Buoy Splunk"s (SPLK) Q1 Earnings?

Splunk (SPLK) is likely to have recorded year-over-year growth in revenues in fiscal 2023 first quarter, driven by solid demand for cloud-based solutions and customer additions. Splunk Inc. SPLK is scheduled to report first-quarter fiscal 2023 (ended Apr 30, 2022) results on May 25, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 447.4%. It pulled off a trailing four-quarter earnings surprise of 115.3%, on average.The San Francisco, CA-based company is expected to have recorded year-over-year higher revenues, driven by solid demand for cloud-based solutions and customer additions.Factors at PlayDuring the quarter, Papa John’s International, Inc. inked a contract with Splunk to leverage data from Splunk Cloud Platform to improve the visibility and performance across more than 3,000 North American stores. The real-time insights are likely to help the restaurant operator cope with the increased demand schedule by aligning its operations accordingly, thereby making critical business decisions to fulfill millions of pizza orders each week. It will also enable it to secure transaction processing and empower vital field operations for smooth functioning. The contract is likely to have generated incremental revenues for Splunk in the quarter.Splunk is playing a critical role in customers’ digital transformation. It is likely to have benefited from the growing adoption of its data platform and security solutions by organizations owing to the rise in perceived cybersecurity threats. For the to-be-reported quarter, management expects total revenues to be between $615 million and $635 million. The Zacks Consensus Estimate for revenues is pegged at $626 million, which indicates growth from the year-ago quarter’s reported figure of $502 million. The consensus estimate for adjusted loss per share is pegged at 72 cents.Earnings WhispersOur proven model does not predict an earnings beat for Splunk for the fiscal first quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here.Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%, with both pegged at a loss of 72 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Splunk Inc. Price and EPS Surprise Splunk Inc. price-eps-surprise | Splunk Inc. QuoteZacks Rank: Splunk has a Zacks Rank #3.Stocks to ConsiderHere are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:Ciena Corporation CIEN is set to release quarterly numbers on Jun 2. It has an Earnings ESP of +6.91% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.The Earnings ESP for NetApp, Inc. NTAP is +2.70% and it carries a Zacks Rank of 3. The company is set to report quarterly numbers on Jun 1.The Earnings ESP for NVIDIA Corporation NVDA is +2.57% and it carries a Zacks Rank of 3. The company is scheduled to report quarterly numbers on May 25.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ciena Corporation (CIEN): Free Stock Analysis Report NetApp, Inc. (NTAP): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Splunk Inc. (SPLK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 20th, 2022

Keysight (KEYS) Tools Deployed by Celona for 5G Private Network

Per the deal, Celona will leverage Keysight (KEYS) KORA solutions to accelerate the deployment of 5G local area network solutions to provide fast private wireless network connectivity. Keysight Technologies, Inc. KEYS recently announced that Celona has selected Keysight’s Open RAN Architect (KORA) validation tools to secure the growing 5G private network deployment across the United States. The deal for an undisclosed amount is likely to simplify the private cellular connectivity within the enterprise market and enable the industry to realize the full potential of a virtualized network architecture with pervasive and connected intelligence at its core.Since its inception in 2019, Celona has been enabling the transition of business enterprises to wireless cellular networks with an end-to-end networking solution. This, in turn, facilitates firms to deploy, operate and integrate LTE/5G cellular technology with their existing infrastructure. Per the deal, Celona will leverage Keysight KORA solutions to accelerate the deployment of 5G local area network solutions, including access points for indoor and outdoor wireless coverage and cloud-native software powered by artificial intelligence. This is widely expected to provide fast private wireless network connectivity.Keysight boasts a robust 5G portfolio. The company’s 5G product design validation solutions ranging from Layer 1 to 7 enable telecom and semiconductor companies to accelerate their 5G initiatives. Further, Keysight’s 5G network emulation solutions facilitate end-to-end processes from development to deployment, accelerating the 5G device architecture. The solutions offer cost-efficient test techniques with high flexibility and control capabilities, reducing time-to-market. Intensive infrastructure investments in 5G deployment and positive trial testing results across the globe are likely to drive the company's long-term growth.Apart from strength in the 5G domain, Keysight’s efforts in other emerging growth markets like IoT and high-speed data centers bode well for the top line. Particularly, management’s focus on Automotive and Energy and Aerospace and Defense domains augurs well in the long haul. The company is expected to benefit from the growing proliferation of electronic content in vehicles, momentum in space and satellite applications and the rising adoption of driver-assistance systems globally.The company is a leading player in the 5G device testing market, offering a comprehensive range of device test solutions based on a common set of hardware and software components. Keysight is reportedly the first test equipment vendor to offer 5G device test solutions for all phases of 5G development – from early 5G research projects through support for pre-5G commercialization to the first-to-market solutions for the trial of the 3GPP 5G NR standards. It works closely with all the key chipset makers and has gained vital insights into varied 5G device test platforms and solutions, making it an ideal choice for the industry for all 5G device testing metrics.Keysight’s software-driven signal analysis and network emulation platforms help carriers expand their 5G device validation services. These include the E7515B UXM 5G wireless test platform, E5080B vector network analyzer, F9650A Compact Antenna Test Range (CATR) chamber and N9020B MXA signal analyzer. While the F9650A CATR chamber supports over-the-air testing in the mmWave frequency range, Keysight’s E5080B vector network analyzer and N9020B MXA signal analyzer measure radio frequency characteristics and functional testing metrics, respectively. These integrated testing tools address a wide range of validation scenarios across any 3GPP-defined frequency band.It has lost 1.8% over the past year compared with the industry’s decline of 3.8%. We remain impressed with the inherent growth potential of this Zacks Rank #3 (Hold) stock.Image Source: Zacks Investment ResearchStocks to ConsiderHere are some stocks in the industry that investors can consider:Advantest Corporation ATEYY, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Earnings estimates for the current year for ATEYY have moved up 10% over the past year, while that for the next fiscal is up 34.3%. Advantest delivered an earnings surprise of 26.7%, on average, in the trailing four quarters.Camtek Ltd. CAMT, carrying a Zacks Rank #2, is another solid pick for investors. It delivered an earnings surprise of 5%, on average, in the trailing four quarters and has a long-term growth expectation of 6.2%.Over the past year, the stock has gained a modest 15.7%. Earnings estimates for the current year for Camtek have moved up 16.2% since May 2021. The company is organized around eight subsidiaries based in the United States, Europe, Japan, China, Hong Kong, Taiwan, Korea and Singapore.Duck Creek Technologies, Inc. DCT carries a Zacks Rank #2. It has a long-term earnings growth expectation of 50% and delivered a stellar earnings surprise of 275%, on average, in the trailing four quarters.Earnings estimates for Duck Creek for the current year have moved up 400% since May 2021. Duck Creek’s functionally-rich solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Camtek Ltd. (CAMT): Free Stock Analysis Report Duck Creek Technologies, Inc. (DCT): Free Stock Analysis Report Keysight Technologies Inc. (KEYS): Free Stock Analysis Report Advantest Corp. (ATEYY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 20th, 2022

Nokia (NOK) Solutions to Boost Output, Offer Flexibility

Nokia's (NOK) MX Boost and Nokia DAC Wi-Fi will offer more flexibility to industries in connecting their assets. Nokia Oyj NOK, with the introduction of MX Boost and Nokia DAC Wi-Fi, is poised to offer industries a more flexible way to connect their assets as well as help achieve reliability and performance for demanding industry use cases.With the help of MX Boost, the industries will now be able to combine multiple radio technologies and spectrum, providing them reliable, high-performance connectivity for their business and mission-critical industrial applications. MX Boost, a Nokia Bell Labs patented innovation, will be deployed at Nokia MX Industrial Edge (MXIE), making it easier for industries to aggregate 4.9G/5G private wireless connectivity paths. It also comes as a blessing for industries with heterogeneous connectivity environments, such as multiple legacy Wi-Fi networks, as it aids in extracting more value from the existing network environment by merging their strengths with unique multiple connectivities.The gradual adoption of private 4.9G/LTE and 5G allows industries to capture new insights and capabilities from the operational data via a secure and low latency network. The potentiality of private 4.9G/LTE and 5G permits it to support demanding applications and deployments of leveraged multiple layers and frequency bands.Nokia DAC Wi-Fi, running on MXIE, is the first operational technology-centric edge solution to enable on-premises Industry 4.0 digitalization applications, workloads and analytics. With this solution, deployment of Wi-Fi 6/6E becomes easier, in turn aiding in meeting the connectivity demands of IT and non-business critical operational technology (OT) applications at any industrial site. The deployment of this solution will also help to realize the benefits of the newest Wi-Fi generation and on-premises edge cloud solution that accelerates OT digitalization.Also, by running on MXIE, the solution can provide the workers with on-demand access to job assignments, task lists, a knowledge base and documentation and facilitate workforce training and knowledge transfer. In warehouses and distribution centers, this solution can act as a reliable hotspot connectivity system to support asset tracking applications.Nokia is on track to achieve sustainable, profitable growth and technology leadership. It aims to accelerate its product roadmaps and cost competitiveness through additional 5G investments. It has been developing its 5G portfolio, strengthening AirScale and advancing the capabilities of its ReefShark chipset.Image Source: Zacks Investment ResearchNokia has lost 5% over the past year compared with the industry’s decline of 10%.It currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Coupa Software Incorporated COUP is a better-ranked stock in the broader Zacks Computer and Technology sector, carrying a Zacks Rank #2 (Buy). Coupa Software has a long-term earnings growth expectation of 22.32%.Coupa Software’s smart and efficient spend-control programs that provide enhanced reporting and analytics have been the primary reason behind its expanding clientele.SAP SE SAP, carrying a Zacks Rank #2, is a key pick for stock investors. SAP has a long-term earnings growth expectation of 5.89%.SAP, with its Rise with SAP solution, was adopted by clients, including Accenture, Canon Production Printing, Exide Industries Limited, NEC Corporation, Qinqin Food, Rising Auto and TELUS.Silicon Motion Technology SIMO also carries a Zacks Rank #2. It has a long-term earnings growth expectation of 9%, with an earnings surprise of 1.05% on average in the trailing four quarters.Silicon Motion has established itself as the leading merchant supplier of client SSD controller to module makers, including most leaders in the United States.  Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nokia Corporation (NOK): Free Stock Analysis Report SAP SE (SAP): Free Stock Analysis Report Silicon Motion Technology Corporation (SIMO): Free Stock Analysis Report Coupa Software, Inc. (COUP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 20th, 2022

NetApp (NTAP), Kyndryl Team up to Boost Data Management

NetApp (NTAP) partners with Kyndryl to develop solutions to aid companies in gaining more insights from unstructured datasets. NetApp NTAP partnered with Kyndryl KD to help companies better organize, manage and gather insights via enhanced data management across on-premises, cloud and edge-computing environments.Kyndryl designs and manages the complex, mission-critical information systems used throughout the world. It reportedly serves more than 4,000 customers in above 60 countries around the world.NetApp, Inc. Price and Consensus  NetApp, Inc. price-consensus-chart | NetApp, Inc. QuoteNetApp will integrate its expertise on public clouds and edge-to-core-to-cloud scalability with Kyndryl's IT infrastructure and managed service expertise to develop the latest solutions.The new solutions will aid enterprises in accessing, analyzing and drawing insights from data stored on multiple platforms and cloud, while enabling a speedier transition of critical applications to the cloud.Customers across sectors would benefit from the partnership by being able to better manage and extract business value from a mountain of unstructured data, such as text-based documents, photographs, audio and video files, and IoT sensors.These companies also plan to collaborate on sophisticated storage infrastructure-as-a-service solutions in the future to address the challenges in the automotive and financial services sector.This will provide customers more flexibility, versatility and value from the use of unstructured data and assist businesses in gaining value from their data.On Mar 16, 2022, NetApp announced the launch of FlexPod XCS. FlexPod XCS will provide an automated platform for modern applications, data and hybrid cloud services. The partnership between these companies will increase accessibility and scalability to offer a simplified hybrid cloud experience.NetApp provides enterprise storage, and data management software and hardware products and services. The company’s product line comprises two storage platforms — FAS and E-Series. The company’s all-flash storage portfolio comprises NVMe-based storage systems and new cloud-based services in order to provide hybrid storage architecture.Key Picks:NetApp currently has a Zacks Rank #3 (Hold).Some better-ranked stocks from the broader technology space are InterDigital IDCC and Pure Storage PSTG. InterDigital currently sport a Zacks Ranks #1 (Strong Buy), whereas Pure Storage carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for InterDigital’s 2022 earnings is pegged at $3.28 per share, increasing 5.2% in the past 60 days. The long-term earnings growth rate is anticipated to be 15%.InterDigital’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 141.13%. Shares of IDCC have declined 14.9% in the past year.The Zacks Consensus Estimate for Pure Storage’s fiscal 2023 earnings is pegged at 86 cents per share, unchanged in the past 60 days. The long-term earnings growth rate is anticipated to be 30.9%.Pure Storage’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 99.2%. Shares of PSTG have gained 37.2% in the past year Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NetApp, Inc. (NTAP): Free Stock Analysis Report InterDigital, Inc. (IDCC): Free Stock Analysis Report Pure Storage, Inc. (PSTG): Free Stock Analysis Report Kyndryl Holdings, Inc. (KD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 20th, 2022